drksId;firstDrksPublishDate;firstPartnerPublishDate;investorInitiated;ethicCommitteeVote;ethic-commission.id;ethic-commission.name;secId.type0;secId.id0;secId.name0;secId.type1;secId.id1;secId.name1;secId.type2;secId.id2;secId.name2;secId.type3;secId.id3;secId.name3;secId.type4;secId.id4;secId.name4;indication.type0;indication.key0;indication.value0;indication.type1;indication.key1;indication.value1;indication.type2;indication.key2;indication.value2;indication.type3;indication.key3;indication.value3;indication.type4;indication.key4;indication.value4;intervention.category0;intervention.value0;intervention.category1;intervention.value1;intervention.category2;intervention.value2;intervention.category3;intervention.value3;intervention.category4;intervention.value4;intervention.category5;intervention.value5;intervention.category6;intervention.value6;intervention.category7;intervention.value7;intervention.category8;intervention.value8;intervention.category9;intervention.value9;type;typeNotInterventional;allocation;masking;control;purpose;assignment;phase;offLabelDrugUse;primaryEndpoint;secondaryEndpoints;recruitmentCountries.key0;recruitmentCountries.value0;recruitmentCountries.key1;recruitmentCountries.value1;recruitmentCountries.key2;recruitmentCountries.value2;recruitmentCountries.key3;recruitmentCountries.value3;recruitmentCountries.key4;recruitmentCountries.value4;recruitmentCountries.key5;recruitmentCountries.value5;recruitmentCountries.key6;recruitmentCountries.value6;recruitmentCountries.key7;recruitmentCountries.value7;recruitmentCountries.key8;recruitmentCountries.value8;recruitmentCountries.key9;recruitmentCountries.value9;recruitmentCountries.key10;recruitmentCountries.value10;recruitmentCountries.key11;recruitmentCountries.value11;recruitmentCountries.key12;recruitmentCountries.value12;recruitmentCountries.key13;recruitmentCountries.value13;recruitmentCountries.key14;recruitmentCountries.value14;recruitmentCountries.key15;recruitmentCountries.value15;recruitmentCountries.key16;recruitmentCountries.value16;recruitmentCountries.key17;recruitmentCountries.value17;recruitmentCountries.key18;recruitmentCountries.value18;recruitmentCountries.key19;recruitmentCountries.value19;recruitmentLocation.type0;recruitmentLocation.value0;recruitmentLocation.city0;recruitmentLocation.type1;recruitmentLocation.value1;recruitmentLocation.city1;recruitmentLocation.type2;recruitmentLocation.value2;recruitmentLocation.city2;recruitmentLocation.type3;recruitmentLocation.value3;recruitmentLocation.city3;recruitmentLocation.type4;recruitmentLocation.value4;recruitmentLocation.city4;recruitmentLocation.type5;recruitmentLocation.value5;recruitmentLocation.city5;recruitmentLocation.type6;recruitmentLocation.value6;recruitmentLocation.city6;recruitmentLocation.type7;recruitmentLocation.value7;recruitmentLocation.city7;recruitmentLocation.type8;recruitmentLocation.value8;recruitmentLocation.city8;recruitmentLocation.type9;recruitmentLocation.value9;recruitmentLocation.city9;recruitmentLocation.type10;recruitmentLocation.value10;recruitmentLocation.city10;recruitmentLocation.type11;recruitmentLocation.value11;recruitmentLocation.city11;recruitmentLocation.type12;recruitmentLocation.value12;recruitmentLocation.city12;recruitmentLocation.type13;recruitmentLocation.value13;recruitmentLocation.city13;recruitmentLocation.type14;recruitmentLocation.value14;recruitmentLocation.city14;recruitmentLocation.type15;recruitmentLocation.value15;recruitmentLocation.city15;recruitmentLocation.type16;recruitmentLocation.value16;recruitmentLocation.city16;recruitmentLocation.type17;recruitmentLocation.value17;recruitmentLocation.city17;recruitmentLocation.type18;recruitmentLocation.value18;recruitmentLocation.city18;recruitmentLocation.type19;recruitmentLocation.value19;recruitmentLocation.city19;startDate;plannedActual;targetSize;studyEnd;monoMultiCentric;national;gender;minAge.amount;minAge.unit;maxAge.amount;maxAge.unit;inclusion;exclusion;address.type0;address.affiliation0;address.form0;address.title0;address.firstname0;address.lastname0;address.streetAndNo0;address.zip0;address.city0;address.land0;address.telephone0;address.fax0;address.email0;address.url0;address.type1;address.affiliation1;address.form1;address.title1;address.firstname1;address.lastname1;address.streetAndNo1;address.zip1;address.city1;address.land1;address.telephone1;address.fax1;address.email1;address.url1;address.type2;address.affiliation2;address.form2;address.title2;address.firstname2;address.lastname2;address.streetAndNo2;address.zip2;address.city2;address.land2;address.telephone2;address.fax2;address.email2;address.url2;address.type3;address.affiliation3;address.form3;address.title3;address.firstname3;address.lastname3;address.streetAndNo3;address.zip3;address.city3;address.land3;address.telephone3;address.fax3;address.email3;address.url3;address.type4;address.affiliation4;address.form4;address.title4;address.firstname4;address.lastname4;address.streetAndNo4;address.zip4;address.city4;address.land4;address.telephone4;address.fax4;address.email4;address.url4;materialSupport.type0;materialSupport.affiliation0;materialSupport.form0;materialSupport.title0;materialSupport.firstname0;materialSupport.lastname0;materialSupport.streetAndNo0;materialSupport.zip0;materialSupport.city0;materialSupport.land0;materialSupport.telephone0;materialSupport.fax0;materialSupport.email0;materialSupport.url0;materialSupport.type1;materialSupport.affiliation1;materialSupport.form1;materialSupport.title1;materialSupport.firstname1;materialSupport.lastname1;materialSupport.streetAndNo1;materialSupport.zip1;materialSupport.city1;materialSupport.land1;materialSupport.telephone1;materialSupport.fax1;materialSupport.email1;materialSupport.url1;materialSupport.type2;materialSupport.affiliation2;materialSupport.form2;materialSupport.title2;materialSupport.firstname2;materialSupport.lastname2;materialSupport.streetAndNo2;materialSupport.zip2;materialSupport.city2;materialSupport.land2;materialSupport.telephone2;materialSupport.fax2;materialSupport.email2;materialSupport.url2;title;acronym;url;publicSummary;scientificSynopsis;recruitmentStatus;publication.category0;publication.key0;publication.type0;publication.value0;publication.category1;publication.key1;publication.type1;publication.value1;publication.category2;publication.key2;publication.type2;publication.value2;publication.category3;publication.key3;publication.type3;publication.value3;publication.category4;publication.key4;publication.type4;publication.value4;url;last-update;
"DRKS00000186";2009/09/29;"[---]*";yes;"Approved";"Vorlage Nr. 104/09";"Ethik-Kommission der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn";"Universal Trial Number (UTN)";"U1111-1111-8467";"[---]*";;;;;;;;;;;;;"ICD10";"Z46.3";"Fitting and adjustment of dental prosthetic device";;;;;;;;;;;;;"Arm 1";"Partial fixed and removable dentures retained by attachments at the anterior remaining teeth are inserted.";"Arm 2";"Partial removable dentures retained by clasps are inserted in the reduced dentition with remaining anterior teeth.";"Arm 3";"Combined fixed and removable dentures retained by telescopic crowns are retained  in a situation with anterior remaining teeth.";;;;;;;;;;;;;;;"Interventional";"[---]*";"Non-randomized controlled trial";"Open (masking not used)";"Active control";"Basic research/physiological study";"Parallel";"N/A";"[---]*";"Final recall after 5 years of follow-up examination or loss of the dentures funktion e.g. by loss of teeth or dentures retention measured by a special device.";"[---]*";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/11/01;"Planned";"75";"[---]*";"Monocenter trial";"National";"Both, male and female";"25";"Years";"75";"Years";"- Patients with a need for treatment with removable partial dentures retained by telescopic crowns, attachments or clasps who were informed about different therapies and decided to be trated by one of the three possibilities<br/>- telescopic crowns can only be used if the teeth can be prepared in one inserting direction, that has to consider the orrientation of the alveolar bone<br/>- only situations with an anterior dentition are accepted with missing molars or missing morals and premolars in both sides of the treated jaw";"- persisting craniomandibular dysfunctions<br/>- massive xerostomia<br/>- handicaps which avoid a minimal oral hygiene<br/>- patients who do not want to accept the follow up examination<br/>- patients older than 75 years<br/>- patients younger than 25 years<br/>- general anamnestic contraindications: chronical gastroesophageal reflux, bulimia, tuberculosis, hepatitis, therapy using a anticoagulant, immuno supression, alcohol or drug addiction, general medical problems avoiding the planned treatment, general medical problems avoiding a follow up examination for 5 years";"Primary Sponsor";"Universität Bonn<br/>Poliklinik für Zahnärztliche Prothetik, Stiftungsproffessur für Oralmedizinische Technologie";"[---]*";"[---]*";"[---]*";"[---]*";"Welschnonnenstr. 17";"53111";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Department of Prosthodontics, Preclinical Education and Dental Materials Science, University of Bonn, Germany";"Mr.";"Dr.";"Stefan";"Bayer";"Welschnonnenstr. 17";"53111";"Bonn";"Germany";"022828722016";"022828722016";"sbayer@uni-bonn.de";"www.uni-bonn.de/zmk";"Contact for Public Queries";"Department of Prosthodontics, Preclinical Education and Dental Materials Science, University of Bonn, Bonn, Germany";"Mr.";"Dr.";"Stefan";"Bayer";"Welschnonnenstr. 17";"53111";"Bonn";"Germany";"022828722016";"022828722016";"sbayer@uni-bonn.de";"www.uni-bonn.de/zmk";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universität Bonn<br/>Poliklinik für Zahnärztliche Prothetik, Stiftungsproffessur für Oralmedizinische Technologie";"[---]*";"[---]*";"[---]*";"[---]*";"Welschnonnenstr. 17";"53111";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Prospective clinical study of the effect of different attachments on oral structures";"[---]*";"[---]*";"The study should examine the effect of different attachments for removable dentures on the tissues of the oral cavity. Especially the periodontal ligament, tooth mobility and bone resorbtion should be studied.";"The effect of the dentures of the patients on oral structures will be measured by the change of tooth mobility, pressure marks and a quantification of the necessity of relining. These parameters should allow conclusions on the bone resorbtion. The tooth mobility is measured in oro-vestibular direction by using Periotest-S (Gulden-Medizintechnik) and also in mesio-distal direction by using a especially constructed device.";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000186";"2014-05-14T13:37:48.474+02:00";
"DRKS00000311";2010/01/13;"[---]*";yes;"Approved";"17/3/05";"Ethik-Kommission der Medizinischen Fakultät der Georg-August-Universität Göttingen";"Universal Trial Number (UTN)";"U1111-1113-2042";"[---]*";;;;;;;;;;;;;"ICD10";"J44";"Other chronic obstructive pulmonary disease";"Other";"[---]*";"OPS 5-32: null";;;;;;;;;;"Arm 1";"In the Control group ventilator support was given only to treat respiratory insufficiency. All patients (including arm 2) are receiving standard care included pain control, chest physiotherapy, early mobilisation and breathing exercises.";"Arm 2";"In the NIPSV group the patient was instructed to use the ventilator for at least 10 hours (intermittent or continuous) for the two first days and on day 3 for additional 6 hours. Afterwards the use is unlimited.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control";"Treatment";"Parallel";"[---]*";"[---]*";"Reintubation and mortality rate in the first 30 days postoperative";"Incidence of pneumonia and blood gas analyses intrahospital";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2005/04/22;"Actual";"40";2009/07/31;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Major lung resection (segmentectomy, lobectomy, bilobectomy, pneumonectomy)<br/>Predicted postoperative lung function (ppoFEV1) between 1,0 l * sec-1 und 1,5 l *sec-1<br/>Maximal oxygen uptake VO2max greater than 10 ml * min-1 * kgKG-1";"Severe congestive heart disease or coranary artery disease<br/>ppoFEV1: < 1,0 l * sec-1<br/>Preoperative VO2max < 10 ml * min-1 * kgKG-1<br/>Age <18 Jahre<br/>Karnofsky Index < 50 or ECOG-WHO Skala >2, respectively<br/>Withdrawal of patients consent";"Primary Sponsor";"Klinik und Poliklinik für Thorax-, Herz- und Gefäßchirurgie<br/>Universitätsmedizin Göttingen";"Mr.";"Prof. Dr. med.";"Friedrich";"Schöndube";"Robert-Koch-Str. 40";"37077";"Göttingen";"Germany";"0551-396001";"0551-396002";"schoendube@med.uni-goettingen.de";"http://thg.med.uni-goettingen.de";"Contact for Scientific Queries";"Klinik und Poliklinik für Thorax-, Herz- und Gefäßchirurgie<br/>Universitätsmedizin Göttingen";"Mr.";"Dr. med.";"Bernd";"Danner";"Robert-Koch-Str. 40";"37077";"Göttingen";"Germany";"0551-396061";"0551-396002";"bdanner@med.uni-goettingen.de";"http://thg.med.uni-goettingen.de";"Contact for Public Queries";"Ev. Krankenhaus Weende, Abt. Pulmologie, Beatmungsmedizin und Schlaflabor";"Mr.";"Dr. med.";"Wolfgang";"Körber";"Pappelweg 5 Bovenden";"37120";"Bovenden";"Germany";"0551-5034-2451";"0551-5034-2452";"koerber-goettingen@t-online.de";"www.ekweende.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget , no external funding (budget of sponsor/PI)";"Klinik und Poliklinik Thorax-, Herz- und Gefäßchirurgie<br/>Universitätsmedizin Göttingen";"Mr.";"Prof. Dr. med.";"Friedrich";"Schöndube";"Robert-Koch-Str. 40";"37077";"Göttingen";"Germany";"0551-396001";"0551-396002";"schoendube@med.uni-goettingen.de";"http://thg.med.uni-goettingen.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Clinical impact of non invasive pressure support ventilation after extubation in major lung resectional surgery";"[---]*";"[---]*";"Chronic obstructive lung disease with reduction of pulmonary function is often coincident with lung cancer and resection of lung parenchyma additionally reduces functional capacity. Thus, optimized bronchiolytic therapy is mandatory and ameliorates pulmonary function in most patients by that revealing functional operability. In patients with persistent borderline or severe reduction of pulmonary function operative risk increases or hinders operative option. These patients are rare, but non-invasive ventilatory support (NIVS) can be a feasible option to diminish operative mortality and morbidity.<br/>For these reasons we conducted a prospective randomized study including patients in need for major lung resection with severe pulmonary dysfunction. Following a preoperative diagnostic and therapeutic algorithm, eligible patients were selected according to study criteria. Preoperatively all patients underwent NIVS (preoperative conditioning) to ameliorate functional capacity and to familiarize themselves with the naso-fascial mask for autonomous utilisation. This provides uncomplicated postoperative use, even early after extubation. Currently, feasibility of preoperative use and postoperative continuation of NIVS is not well investigated, especially for these high risk patients.";"In major lung surgery for pneumonectomy and lobectomy postoperative mortality is up to 11.5% and 4%, respectively. In a recent study mortality rate decreased, but postoperative pneumonia or acute respiratory failure was still the main cause of death in up to 46%. Especially in patients with reduced forced expiratory volume at one second (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) postoperative mortality and morbidity increases inversely proportional to the lung function. Non-invasive pressure support ventilation support (NIPSV) has several advantages in respiratory care and is superior to invasive ventilation in acute respiratory distress. In severe exacerbation of chronic obstructive pulmonary disease application of NIPSV reduce mortality rate and decrease hospital stay. In postoperative care NIPSV had positive effects on functional lung parameters after general surgery. In pulmonary complications after major lung resection NIPSV can reduce mortality in acute respiratory failure after lung resection surgery. In prophylactic use NIPSV ameliorates functional lung parameters and arterial oxygenation. No data are available concerning the impact on clinical outcome in using prophylactic NIPSV in patients undergoing major lung resection with predicted low FEV1 indicating high operative risk.";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000311";"2012-01-02T12:19:06.042+01:00";
"DRKS00000109";2009/04/27;2009/03/09;yes;"Approved";"Bearb-Nr.: 2693";"Ethik-Kommission der Ärztekammer Hamburg";"EudraCT-Number";"2005-003026-26";"[---]*";"Primary Registry-ID";"NCT00858793";"ClinicalTrials.gov";"PEI-No.";"203/01";"[---]*";;;;;;;"ICD10";"B21";"Human immunodeficiency virus [HIV] disease resulting in malignant neoplasms";;;;;;;;;;;;;"Arm 1";"High-dose chemotherapy with transplantation of autologous or allogeneic gene-modified stem cells";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"I-II";"[---]*";"Safety Parameters (Adverse Events), ECOG performance status and laboratory safety tests(RCR-testing)";"Efficacy parameters CR or PR and any relapse of ARL, level and kinetics of engraftment and level of gene marking, Viral load and CD4 counts";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2008/12/02;"Actual";"10";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"65";"Years";"- Female and male patients of any ethnic group aged between 18 and 65 years<br/>-HIV-positive patients with malignant diseases of the blood (NHL, Hodgkin disease, plasmocytoma, acute and chronic leukaemia)<br/>-Patients must receive HAART(HAART should be unchanged since 1 month before inclusion in the study)";"-Any of the following conditions:<br/>  o congestive heart failure (NYHA > II)<br/>  o documented EBV, HBV or HCV infection (only for allogeneic PBSCT)<br/>  o creatinine clearance < 60 ml/min<br/>  o left ventricular ejection fraction < 40%<br/>  o bilirubin > 2 mg/dl<br/>-Not-treated opportunistic infection<br/>-Not-treated CNS involvement of lymphoma<br/>-Isolated CNS relapse of the lymphoma without other evidence of active disease<br/>-More than 10% of bone marrow involved <br/>-Between 2 and 5 x 10^6 autologous CD34+ cells /kg body weight obtained after<br/>leukapheresis and CD34 enrichment<br/>- Women of child-bearing potential not under adequate contraceptive protection<br/>- Women who are pregnant or breast feeding<br/>- Known history of drug-, medication- or alcohol abuse within the last 12 months preceding the study<br/>-Participation in another study with an investigational drug within less than one month prior to this study<br/>-Simultaneous participation in a study with an investigational drug<br/>- Presence of any disease likely to require procedures altering the schedule of this study<br/>- Patients who are unable or unwilling to meet the requirements of the protocol<br/>-Patients with a history of seizures, central nervous system disorders or psychiatric disability thought to be clinically significant in the opinion of the investigator<br/>-Patients with limited mental capacity to the extent that he/she cannot provide informed consent or information regarding adverse events of the study medication<br/>-Patients with any clinically meaningful renal, hepatic, respiratory or cardiovascular disease<br/>-Patients who will not accept transfusions of blood products";"Primary Sponsor";"Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation, Onkologisches Zentrum, Universitätsklinikum Hamburg-Eppendorf";"Mr.";"Prof. Dr. med. ";"Nicolaus";"Kröger";"Martinistr. 52";"20246";"Hamburg";"Germany";"+49 40 7410 5-4851";"+49 40 7410 5-3795";"nkroeger@uke.uni-hamburg.de";"[---]*";"Contact for Scientific Queries";"Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation, Universitätsklinikum Hamburg-Eppendorf";"Mr.";"Prof. Dr. rer. nat.";"Boris";"Fehse";"Martinistr. 52";"20246";"Hamburg";"Germany";"+49 40 7410 5-5518";"+49 40 7410 5-5468";"fehse@uke.de";"http://www.foerderverein-kmt.de/index.php?id=unser_team";"Contact for Public Queries";"Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation, Universitätsklinikum Hamburg-Eppendorf";"Mr.";"Prof. Dr. med.";"Nicolaus";"Kröger";"Martinistr. 52";"20246";"Hamburg";"Germany";"+49 40 7410 5-4851";"+49 40 7410 5-3795";"nkroeger@uke.de";"http://www.foerderverein-kmt.de/index.php?id=unser_team";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Germany";"[---]*";"[---]*";"[---]*";"http://www.bmbf.de/index.php";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"High-dose chemotherapy with transplantation of gene-modified haematopoietic stem cells for HIV-positive patients with malignant diseases indicating an HSCT";"[---]*";"[---]*";"This study intends to offer HIV-positive patients requiring a haematopoietic stem cell transplantation an additional gene-therapy treatment against HIV.";"High-dose chemotherapy followed by the transplantation of hematopoietic stem/progenitor cells protected with an antiviral gene in HIV-positive patients with malignant diseases has two major goals: 1. The intensified chemotherapy with stem cell rescue aims to radically eliminate malignant cells and to induce continuous complete remission (CCR) in the patient. 2. The transfer of a highly effective antiviral gene (M87o) into the stem cells aims to reconstitute a competent immune system that includes an ideally complete T-cell repertoire and monocytes that are protected against HIV-infection.";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000109";"2012-09-24T09:46:48.090+02:00";
"DRKS00006362";2014/09/03;2013/07/22;yes;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT01941550";"ClinicalTrials.gov";"Sponsor-ID";"13-005";"RWTH Aachen University";;;;;;;;;;"Free text";"[---]*";"High-Risk Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: Cabazitaxel chemotherapy";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"II";"[---]*";"- Complete pathological response rate; time frame: 5 years; Primary endpoint: overall or cancer specific survival nor progression-free survival(PFS) in 5 years. Composite measurement.<br/>Key-parameters:<br/>Complete pathohistological remission<br/>Intra/perioperative compl.<br/>PFS<br/>Metastasis-FS<br/>Biochemical, radiological, clinical PFS and androgen-deprivation FS<br/>Objective progr. during cabazitaxel therapy (cab.th.) and post surgery<br/>PSA response at the end of cab.th.<br/>PSA progression after 12 w. of cab.th.<br/>Percentage of pat. with undetectable PSA (<0.1 ng/ml) post surgery<br/>Relationship between PSA kinetics, histol. response and MRI response<br/>Role of pathohistol. parameters such as intraductal, cribriform growth patterns and effect on response<br/>Immunohistochemical evaluation of prostate biopsy and radical prostatectomy specimens of markers potentially associated with chemoresistance: growth differentiation factor 15, surviving, beta-tubuline I & II, p53, bcl-2,<br/>Measurement of the serum concentrations of free circulating mDNA<br/>";"[---]*";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"University Hospital Aachen";"Aachen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/07/31;"[---]*";"35";"[---]*";"[---]*";"[---]*";"Male";"18";"Years";"[---]*";"no maximum age";"-  Surgically resectable high risk prostate cancer with a 5-year relapse probability ≥<br/>             60% according to the Kattan pre-operative nomogram (cancer 2009, 115: 1005-1010)<br/><br/>               -  no prior therapy for prostate cancer such as androgen deprivation therapy,<br/>                  radiation therapy, or chemotherapy<br/><br/>               -  ECOG performance status 0-1<br/><br/>          -  No evidence of active infection<br/><br/>               -  Hemoglobin >9.0 g/dL<br/><br/>               -  Absolute neutrophil count >1.5 x 109/L,<br/><br/>               -  Platelet count >100 x 109/L,<br/><br/>               -  AST/SGOT and/or ALT/SGPT <2.5 x ULN;<br/><br/>               -  Total bilirubin <1.0 x ULN,<br/><br/>               -  Serum creatinine <1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance<br/>                  will be calculated according to CKD-EPI formula and patients with creatinine<br/>                  clearance <60 mL/min should be excluded)<br/><br/>               -  Patient information and signature of informed consent<br/><br/>               -  Male ≥ 18 years<br/><br/>               -  Patients of reproductive age must take appropriate contraceptive precautions<br/>                  during and for 6 months after the end of their participation in the study<br/>";"-  Evidence of lymph node, visceral or bone metastases<br/><br/>               -  previous major intrapelvic surgery<br/><br/>               -  previous radiation therapy to the small pelvis<br/><br/>               -  any type of malignancies within the last 5 years except basalioma and non-muscle<br/>                  invasive urothelial cancer of the urinary bladder<br/><br/>               -  previous chemotherapy with taxanes (docetaxel, paclitaxel, cabazitaxel) for any<br/>                  indication<br/><br/>               -  Hypersensitivity to the active substance or to any of the excipients<br/><br/>               -  Known or suspected brain metastases or leptomeningeal metastases<br/><br/>               -  Active or symptomatic viral hepatitis or chronic liver disease<br/><br/>               -  Serious or uncontrolled co-existent non-malignant disease, including active and<br/>                  uncontrolled infection<br/>";"Primary Sponsor";"RWTH Aachen University";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Department of Urology";"[---]*";"[---]*";"[---]*";"Axel Heidenreich, Prof.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Department of Urology";"[---]*";"[---]*";"[---]*";"Axel Heidenreich, Prof.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Neoadjuvant Chemotherapy With Cabazitaxel in High Risk Prostate Cancer Patients Prior to Radical Prostatectomy";"CLUBNET";"[---]*";"This study is aimed at evaluating the efficacy regarding the response rate and<br/>      metastasis-free survival time of cabazitaxel as a neoadjuvant treatment in patients with<br/>      high risk prostate cancer.<br/>";"Patients will be treated by 6 cycles of Cabazitaxel 25 mg/m2 every three weeks and extended<br/>      radical prostatectomy and extended pelvic lymphadenectomy 4 weeks after completion of<br/>      chemotherapy. Multiparametric MRI will be performed at baseline, after 3 cycles and after 6<br/>      cycles. If there will be evidence of clinical progression after 3rd cycle, patients can be<br/>      removed from the study and given local therapy, including radical prostatectomy or external<br/>      beam radiotherapy, at the discretion of the patient's physicians. If patients have evidence<br/>      of response, they continue on treatment for a total of 6 cycles. If multiparametric MRI<br/>      demonstrates stable disease an individual risk-benefit analysis has to be performed with<br/>      regard to continuing or to stopping the neoadjuvant treatment since the definition stable<br/>      disease includes patients with ≤ 20% tumour shrinkage or tumour progression<br/>";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006362";"2016-01-29T15:41:23.802+01:00";
"DRKS00006867";2014/10/15;"[---]*";no;"Approved";"Bo/29/2014";"Ethikkommission bei der Ärztekammer Niedersachsen";;;;;;;;;;;;;;;;"Free text";"[---]*";"healthy female subjects";;;;;;;;;;;;;"Arm 1";"Over a period of eight weeks, study participants have to take one pill daily of an dietary supplement. One pill contains of 250 mg magnesium, 12 mg α-TE vitamin E, 6 mg Rosavine (of 200 mg Rhodiola-rosea-extract); 1,5 mg vitamin B2; 1 mg vitamin B6; 400 µg folic acid; 10 µg vitamin D3; 5 µg vitamin B12.";"Arm 2";"Over a period of eight weeks, study participants have to take one pill daily of the placebo, which contains bulking agents. This pill is optical and sensorial identically equal with the dietary supplement. ";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Basic research/physiological study";"Parallel";"N/A";"N/A";"Change in the stress tolerance compared to placebo and within the eight-week intervention period, respectivly measured as a change in mental performance and visual attention under stress, using Trail Making Test (TMT) before and after an acute stress stimulus.";"1. Change in stress tolerance compared to placebo and within the eight-week intervention period, measured as a change in mental performance and visual attention in the Colour Word Test (CWT; Duration: 10 min) before and during an acute stress stimulus.<br/><br/>2. Change (compared to placebo and within 8 weeks) regarding the subjective reason-stress perception (according to the Perceived Stress Questionnaire).<br/><br/>3. Change (compared to placebo and within 8 weeks) regarding the subjective acute stress perception (according to the General Stress Questionnaire (ASF)) before and after an acute stress stimulus. <br/><br/>Other control parameters for the measurement of the stress response are: cortisol and alpha-amylase in the saliva, blood pressure and heart rate.<br/><br/>Furthermore, the following parameters and their changes are analyzed as a secondary target for all time periods (from week 0 to week 4 and week 0 to week 8): <br/>• Status of vitamins D3 and E, folic acid, vitamins B2, B6, B12 and the mineral magnesium<br/>• homocysteine<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"other";"Institut für Lebensmittelwissenschaft und Humanernährung, Abteilung: Ernährungsphysiologie und Humanernährung, Hannover ";"Universität Hannover";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Planned";"150";"[---]*";"Monocenter trial";"National";"Female";"20";"Years";"50";"Years";"• Age: 20-50 years <br/>• healthy women<br/>• Written consent of the subjects after detailed oral and written explanation of the course content, requirements and risks <br/>• Ability and willingness of study participants to follow the instructions of the study leader (compliance with study conditions, taking the test product according to the dosage recommendation, etc.)<br/>";"• severe chronic diseases (malignant tumors, diabetes mellitus type 1 and type 2, etc.), manifest cardiovascular disease (e.g. angina pectoris, heart failure), kidney failure, liver disease <br/>• Mental Disorders (ADHD, depression, panic attacks, anxiety, etc.) <br/>• diagnosed bleeding disorders as well as taking anticoagulant medications e.g. warfarin (except aspirin) <br/>• known allergy or intolerance to one of the ingredients contained in the test product <br/>• chronic gastrointestinal disorders (ulcerative colitis, Crohn's disease, pancreatic insufficiency) <br/>• heart surgery (stent, bypass, pacemaker) or digestive tract (exceptions: removal of appendix or gall bladder) <br/>• inflammation of the oral cavity associated with gingival bleeding (e.g. gingivitis, periodontitis, mucositis) <br/>• imminent surgery <br/>• ingestion of nutrient supplements, which contain Rhodiola rosea (Rhodiola) <br/>• taking anti-depressants, etc. <br/>• addiction to alcohol, drugs and / or medicines <br/>• Pregnancy and lactation <br/>• BMI > 30 kg / m2 <br/>• incapacitated subjects <br/>• refusal or withdrawal of consent by the subject<br/>• Simultaneous participation in another clinical trial or to participate in the last 30 days<br/>";"Primary Sponsor";"Rottapharm | Madaus GmbH - Madaus GmbH -";"[---]*";"[---]*";"[---]*";"[---]*";"Colonia-Allee 15";"51067";"Köln";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Leibniz Universität Hannover, Institut für Lebensmittelwissenschaft und Humanernährung, Abteilung Ernährungsphysiologie und Humanernährung";"Ms.";"Dipl. troph.";"Tina";"Heinz";"Am Kleinen Felde 30";"30167";"Hannover";"Germany";"0511/ 762 5931";"[---]*";"heinz@nutrition.uni-hannover.de";"http://www.nutrition.uni-hannover.de/nutrition.html";"Contact for Public Queries";"Leibniz Universität Hannover, Institut für Lebensmittelwissenschaft und Humanernährung, Abteilung Ernährungsphysiologie und Humanernährung";"Ms.";"Dipl. troph.";"Tina";"Heinz";"Am Kleinen Felde 30";"30167";"Hannover";"Germany";"0511/ 762 5931";"[---]*";"heinz@nutrition.uni-hannover.de";"http://www.nutrition.uni-hannover.de/nutrition.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Rottapharm | Madaus GmbH Madaus GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Colonia-Allee 15";"51067";"Köln";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Effect of a nutritional supplement with vitamins, magnesium and Rhodiola rosea extract on psychophysiological stress reactions in women during periods of stress";"[---]*";"[---]*";"Stress is defined as a permanent perceived physical and / or mental tension. Affected individuals often suffer from stress related symptoms such as fatigue, exhaustion, depressive moods and further stress reactions in other organ systems. Stress states are not only associated with immediate adverse health effects. They also favor the emergence of nutritional deficits, which result from a stress-induced change in the diet. A lack of nutrients promotes the stress symptoms. Therefore, it is of interest to check whether a particular dietary supplement can affect the stress management (stress tolerance) positive. <br/><br/>The study product contains an extract of Rhodiola (Rhodiola rosea), vitamins E, D3, folic acid, and vitamins B2, B6 and B12 and the mineral magnesium. These micronutrients have an influence on the perception of stress and a deficiency can result in fatigue, poor concentration, irritability and mild depressive moods. <br/><br/>The aim of the present nutritional study is to investigate the influence of a dietary supplement with vitamins, magnesium and Rhodiola rosea extract on the stress tolerance of women aged 20 to 50 years. The female subjects are physically healthy, but feel stressed and exhausted due to family and work multiple exposures. Furthermore, the stress associated nutrient deficiencies shall be compensated and improved by the supplementation of selected micronutrients. This nutritional study is done as a randomized, placebo-controlled, double-blind intervention trial.<br/>";"Stress is defined as a permanent perceived physical and / or mental tension. Affected individuals often suffer from stress related symptoms such as fatigue, exhaustion, depressive moods and further stress reactions in other organ systems. Stress states are not only associated with immediate adverse health effects. They also favor the emergence of nutritional deficits, which result from a stress-induced change in the diet. A lack of nutrients promotes the stress symptoms. <br/><br/>The study product contains an extract of Rhodiola (Rhodiola rosea). Clear evidences of the scientific literature show that the intake of Rhodiola preparations can reduce stress-related fatigue and increase attention as well as concentration. Furthermore, the study product contains vitamins E, D3, folic acid, and vitamins B2, B6 and B12 and the mineral magnesium. These ingredients fulfil major functions in the central nervous system and are involved in the formation of neurotransmitters of the central nervous system such as adrenalin, noradrenaline and serotonin. These micronutrients have an influence on the perception of stress and a deficiency can result in fatigue, poor concentration, irritability and mild depressive moods. <br/><br/>The aim of the present nutritional study is to investigate the influence of a dietary supplement with vitamins, magnesium and Rhodiola rosea extract on the stress tolerance of women aged 20 to 50 years and to establish a possible adaptogen effect. The female subjects are physically healthy, but feel stressed and exhausted due to family and work multiple exposures. Furthermore, the stress associated nutrient deficiencies shall be compensated and improved by the supplementation of selected micronutrients. The process of the target parameters is observed over a study period of eight weeks, whereby the study days take place in week 0 (t0), at week 4 (t4) and at week 8 (t8). This nutritional study is done as a randomized, placebo-controlled, double-blind intervention trial.<br/>";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006867";"2015-10-22T12:10:30.137+02:00";
"DRKS00011060";2017/06/02;"[---]*";yes;"Approved";"121/16";"Ethikkommission der Medizinischen Fakultät der Otto-von-Guericke-Universität Magdeburg";;;;;;;;;;;;;;;;"ICD10";"D45";"Polycythaemia vera";;;;;;;;;;;;;"Arm 1";"Appointments for bloodletting following standard procedure, based on lab values (data taken from retrospective medical records).";"Arm 2";"Appointments for bloodletting using the model, which is using lab values. The evaluation period is planned to be three cycles. Depending on the results this can be changed.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Non-randomized controlled trial";"Open (masking not used)";"Historical";"Treatment";"Parallel";"N/A";"N/A";"Quality of model predictions w.r.t. normal indication for bloodletting (only blood count)";"Precision of prognosed hematocrit (model response compared to blood count)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"[---]*";"Magdeburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/10/02;"Actual";"20";"[---]*";"Monocenter trial";"National";"Male";"18";"Years";"[---]*";"no maximum age";"PV patient";"Chemotherapy";"Primary Sponsor";"Universitätsklinikum Magdeburg A.ö.R.Universitätsklinik für Hämatologie und Onkologie";"Mr.";"Prof. Dr.";"Thomas";"Fischer";"Leipziger Str. 44";"39120";"Magdeburg";"Germany";"+49 391 67-13266";"+49 391 67-13267";"thomas.fischer@med.ovgu.de";"http://www.khae.ovgu.de/";"Contact for Scientific Queries";"Institut für Mathematische OptimierungFakultät für MathematikOtto-von-Guericke Universität Magdeburg";"Mr.";"[---]*";"Manuel";"Tetschke";"Universitätsplatz 2";"39106";"Magdeburg";"Germany";"+49-391-67 51449";"+49-391-67 11171";"tetschke@ovgu.de";"http://www.mathopt.de/";"Contact for Public Queries";"Institut für Mathematische OptimierungFakultät für MathematikOtto-von-Guericke Universität Magdeburg";"Mr.";"[---]*";"Manuel";"Tetschke";"Universitätsplatz 2";"39106";"Magdeburg";"Germany";"+49-391-67 51449";"+49-391-67 11171";"tetschke@ovgu.de";"http://www.mathopt.de/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"European Research Council Executive Agency";"[---]*";"[---]*";"[---]*";"[---]*";"Place Charles Rogier 16";"1210";"Saint-Josse-ten-Noode (Brussels)";"Belgium";"[---]*";"[---]*";"[---]*";"https://erc.europa.eu/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Patient-specific treatment of Polycythemia<br/>vera using a model of erythropoiesis ";"MODEST-PV";"https://mathopt.de/ERC/POLYCYTHEMIA/";"In patients who suffer from the disease polycythemia vera (PV) the production of blood is not working normally. The body is especially producing too many red blood cells, which increases the risk for the blood to clot and thus can lead to strokes or heart attacks. One possible therapy option is the periodical bloodletting of approx. 500 ml of blood. This leads to a decrease of the number of red blood cells. The timing of these therapies is determined by the physician. Unfortunately, until now the best time point for the intervention can only be guessed. Thus there is a possibility for the treatment to be too late (and therefore increase the risk for clotting) or too be too soon (and thus decrease the quality of life of the patient further). The goal of this study is to use mathematical modelling and optimization to enable the physician to accurately simulate the behaviour of the patients blood and to use this information to find the best point in time for the therapies.<br/>Subjects are patients suffering from PV, who are under surveillance in the hematologic clinic on a regular basis. For those patients the next treatment appointments will be computed using their lab results and our model. The control group will be recruited out of retrospective data.";"Polycythemia vera is a chronic myeloproliferative<br/>neoplasm, i.e. the production of blood cells is increased. Most prominently the erythrocytes, or red blood cells (RBCs) are affected which causes the main problems for the patients: If the ratio of erythrocytes to the whole blood volume, which in medical terms is called hematocrit, exceeds a certain threshold, the blood cells may clot and<br/>thus can cause thromboembolic events. This can lead e.g. to a stroke, heart attack or pulmonary embolism. Therefore if untreated, the mean life expactancy of patients suffering from PV is only about 18 month. <br/>The basic therapy of PV is blood-letting (phlebotomy) of about 500 ml blood on a regular basis. As the body is compensating the bloodloss through plasma nearly instantly but needs several weeks to produce new red blood cells, the hematocrit can temporarily be reduced using this<br/>treatment. In severe cases this procedure is not sufficient and there is also the need to use chemotherapy (or a combination of both). Until now it is not known, how to compute the frequencies and volumes of the phlebotomies to give an optimal outcome for the patient. This<br/>study tries to give an answer to this open question using mathematical modeling, numerical simulation, parameter estimation and optimization.";"Recruiting suspended on temporary hold ";"Paper";"[---]*";"[---]*";"Tetschke, M., Lilienthal, P., Pottgiesser, T., Fischer, T., Schalk, E., & Sager, S. (2018). Mathematical modeling of RBC count dynamics after blood loss. Processes, 6(9), 157.";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011060";"2019-07-08T10:36:40.911+02:00";
"DRKS00011058";2016/09/29;"[---]*";yes;"Approved";"A 2016-0155";"Ethik-Kommission an der Medizinischen Fakultät der Universität Rostock";;;;;;;;;;;;;;;;"Free text";"[---]*";"Other chronic pain";"ICD10";"R52.2";"Other chronic pain";;;;;;;;;;"Arm 1";"Systemic pain therapy: 90mg Arcoxia (Etoricoxib) once daily, taken orally,<br/>50mg Tapentadol retard (Tapentadol) twice daily, taken orally,<br/>40mg Pantozol (Pantoprazol) once daily, taken orally";"Arm 2";"Systemic pain therapy: 90mg Arcoxia (Etoricoxib) once daily, taken orally,<br/>50mg Tapentadol retard (Tapentadol) twice daily, taken orally,<br/>40mg Pantozol (Pantoprazol) once daily, taken orally <br/>+ local application of Ropivacain via a catheter";"Arm 3";"Sytemic pain therapy: 90mg Arcoxia (Etoricoxib) once daily, taken orally,<br/>50mg Tapentadol retard (Tapentadol) twice daily, taken orally,<br/>40mg Pantozol (Pantoprazol) once daily, taken orally<br/>+ preoperative placement of a Transversus-Abdominis-Plane-catheter for the continuous application of Ropivacain";;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"No";"Differences in the intensity of pain between the patients with systemic pain therapy und the patients with Transversus-Abdominis-Plane-catheter; a) postoperative day 0-5: questionnaire; b) 6 weeks: postoperative: telephone interview; c) 3 months postoperative: telephone interview";"Possible differences in the intensity of pain between the patients with the adjuvant pain therapies local application of Ropivacain or Transversus-Abdominis-Plane-catheter;<br/>a) postoperative day 0-5: questionnaire; b) 6 weeks postoperative: telephone interview; c) 3 months postoperative: telephone interview ";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik und Poliklinik für Anästhesiologie und Intensivtherapie";"Rostock";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/02/03;"Actual";"75";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Patients (ASA I-III), which will be undergoing surgery with the need of anterior iliac bone crest harvesting";"Rheumatic diseases, chronic pain of lumbar spine, Kox osteoarthritis, knee or hip prosthesis, earlier iliac bone crest harvesting, intolerance of local anaesthetics or other pain killers, abuse of opioids, chronic intake of pain killers, psychiatric diseases, infections of the abdominal wall, adiposity per magna (BMI≥ 40) ";"Primary Sponsor";"Universitätsklinikum Rostock";"[---]*";"[---]*";"[---]*";"[---]*";"Schillingallee 35";"18057";"Rostock";"Germany";"[---]*";"[---]*";"[---]*";"www.med.uni-rostock.de";"Contact for Scientific Queries";"Universitätsklinikum Rostock";"Mr.";"PD Dr. med.";"Matthias";"Janda";"Schillingallee 35";"18057";"Rostock";"Germany";"+493814946401";"+493814946402";"matthias.janda@uni-rostock.de";"www.med.uni-rostock.de";"Contact for Public Queries";"Universitätsklinikum Rostock";"Mr.";"PD. Dr. med.";"Matthias";"Janda";"Schillingallee 35";"18057";"Rostock";"Germany";"+493814946401";"+493814946402";"matthias.janda@uni-rostock.de";"www.med.uni-rostock.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsklinikum Rostock";"[---]*";"[---]*";"[---]*";"[---]*";"Schillingallee 35";"18057";"Rostock";"Germany";"[---]*";"[---]*";"[---]*";"www.med.uni-rostock.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Pilot study to compare pain therapy of donor site pain of iliac bone crest harvesting: Comparison between systemic pain therapy, local application of Ropivacain and Transversus-Abdominis-Plane-catheter";"STHBK";"[---]*";"This examination focuses on patients with iliac bone crest harvesting as a part of an operation. Background for the procedure is the use of a healthy part of the body for the repair of a disturbed part. To avoid a further reduction, the goal is to optimize in particular the pain therapy of the beforehand healthy region, meaning the region of the iliac crest. There are existing different attempts at treating the pain located there, which shall be compared regarding their effectiveness. Therefore, three groups will be formed in this study: On one hand there is the traditional therapy with pain killers which will be administered intravenous or as pills or drops and which are reducing the sensitivity of pain in the entire body. In the second and third group a local therapy will be administered additionally, meaning a therapy limited to the region of the iliac crest. The administration will be carried out either with giving local anaesthetics via a catheter placed during the surgery or with easing the abdominal layers flatting against the iliac crest via an ultrasound guided placement of a pain catheter. Before and after surgery the patients will be asked for the intensity of their pain directly after surgery and the five following days. There will be additional questioning of occurring pain six weeks and three months after the surgery via telephone.";"Regarding iliac bone crest harvesting for surgical treatment of other, initially morbidity associated regions, like maxillary or oropharyngeal reconstruction, spinal fusion surgery or treatments of distal extremities, one has to recognize the problems of creating a new morbidity not existing before. As a consequence this can lead to pain worse than at the site surgery was primary carried out and furthermore can cause distress and a delayed discharge from the hospital. Due to general recognition of iliac bone crest harvesting as leading procedure for the treatment of primary morbidities it raises the question of the optimal treatment of the created morbidity, with the most frequent complication of acute and chronic pain.<br/>In this pilot study, a comparison of the effectiveness of pain therapy for iliac bone crest harvesting between the local application of Ropivacain via a catheter and the preoperative provision of a TAP-catheter will be conducted, as it has not been reported previously. As a third group a control group, which will receive a systemic pain therapy, will be included.<br/>";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011058";"2020-04-19T19:40:06.037+02:00";
"DRKS00004250";2012/07/25;"[---]*";yes;"Approved";"278/12";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";"Universal Trial Number (UTN)";"U1111-1132-6553";"[---]*";;;;;;;;;;;;;"ICD10";"M51.2";"Other specified intervertebral disc displacement";;;;;;;;;;;;;"Arm 1";"a) Education:<br/>The advising clinician educates the patient extensively in pathology and prognosis of his condition. He emphasizes the good prognosis and advices strongly general activity and movement. The patient receives some written information. <br/><br/>b) mechanical traction:<br/>The patient applies constant mechanical traction using the „Saunders Lumbar HomeTrac” (Ormed DJO 2011) every two hours during the day. Treatment time is five to ten minutes. The patient uses a traction force of one half up to two third of body weight. The appropriate level is set by the patient using a hand held pump. A marker is placed on the pump, indicating the appropriate intensity of traction.<br/>The patient applies the traction for three to four days. Then a follow up appointment is scheduled. A clinician conducts a reassessment of the relevant signs and symptoms and is available for the patient’s questions. If no adverse events are identified, the patient goes on with the traction protocol. The clinician encourages the patient to apply the intervention regularly. After seven to eight days another follow up appointment is scheduled. The intervention stops after two weeks.<br/>Following end of the intervention and the final reassessment, the clinician provides the patient with an advice for further management of his disorder according to the current situation.<br/><br/>";"Arm 2";"The protocol in the control group is identical besides the fact that the patients apply traction only with an intensity of 10 – 20 % of bodyweight. ";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control";"Treatment";"Parallel";"N/A";"[---]*";"German version of Oswestry Disability Index Deutsche Version des Oswestry Disability Index (ODI) <br/>after 2 weeks / 6 weeks / 1 year<br/><br/>Success is defined as 50 % improvement in ODI. ";"- German version of Fear Avoidance Belief Questionaire (FABQ) (Staerkle et al. 2004)<br/>- Pain location - determined by templates (Werneke und Hart 2004, Werneke und Hart 2003)<br/>- Intensity of back pain and leg pain determined Visual Analog Scale (Childs et al. 2005)<br/>- Neurological signs and symptoms<br/>- Days of sick leave since entering the study<br/>- Use of medication <br/>- Patient specific functional outcome score (Bogduk 2007, Stratford 1995)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Zentrale Physiotherapie";"Freiburg im Breisgau";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/10/15;"Actual";"66";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"65";"Years";"a)Age 18 - 65,  male / female<br/>b)Low Back Pain with nerve root involvement<br/>c)symptom duration 4 - 12 weeks before inclusion in study<br/>d)leg pain > back pain<br/>e)leg pain > or = 4/10 VAS<br/>f)No centralization of symptoms with repeated movement testing or static loading strategies";"- preceded spine surgery<br/>- known serious spine patholohgies: cancer, fracture, infectious disease, serious osteoporosis, systemic disease<br/>- other serious pathologies<br/>- epidural injection in the preceding two weeks<br/>- current pregnancy<br/>- Involvement of central nervous system: including cauda equina syndrome or existence pathologic reflexes<br/>- known inability to comply with the treatment protocol<br/>- chronic LBP (> 3 months)<br/>- centralization of symptoms with repeated movement testing or static loading strategies";"Primary Sponsor";"UNIVERSITÄTSKLINIKUM FREIBURG<br/>Akademie für medizinische Berufe";"Mr.";"MSc";"Florian";"Sandeck";"Fehrenbachallee 8";"79106";"Freiburg";"Germany";"+49 761 270-64000";"+49 761 270-64030";"florian.sandeck@uniklinik-freiburg.de";"www.uniklinik-freiburg.de/physiotherapieschule";"Contact for Scientific Queries";"PULZ im Rieselfeld";"Mr.";"[---]*";"Georg";"Supp";"Rieselfeldallee 12";"79111";"Freiburg";"Germany";"+49 761 443050";"+49 761 443060";"georg@pulz-freiburg.de";"www.pulz-freiburg.de";"Contact for Public Queries";"Abteilung Sportorthopädie <br/>Universitätsklinik Freiburg";"Mr.";"Dr. med.";"Hans";"Brauns";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"+49 76127074750";"+49 76127074750";"forschung-physiotherapie@uniklinik-freiburg.de ";"http://www.uniklinik-freiburg.de/dot/live/patientenversorgung/Sport.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"UNIVERSITÄTSKLINIKUM FREIBURG<br/>Akademie für medizinische Berufe<br/>";"[---]*";"[---]*";"[---]*";"[---]*";"Fehrenbachallee 8";"79106";"Freiburg";"Germany";"+49 761 270-64000";"+49 761 270-64030";"florian.sandeck@uniklinik-freiburg.de";"www.uniklinik-freiburg.de/physiotherapieschule";"Institutional budget, no external funding (budget of sponsor/PI)";"PULZ im Rieselfeld";"[---]*";"[---]*";"[---]*";"[---]*";"Rieselfeldallee 12";"79111";"Freiburg";"Germany";"+49 761 443050";"+49 761 443060";"georg@pulz-freiburg.de";"www.pulz-freiburg.de";;;;;;;;;;;;;;;"Intensive home traction for acute and subacute patients with sciatica";"CPR-HT-2011";"[---]*";"For treatment of acute low back pain radiating in the leg, doctors and physiotherapists use a variety of treatment options. It is the aim of these treatment protocols to reduce pain and resolve disabilities in daily live as fast as possible. <br/>Treatment options, used on a regular basis are:<br/>• Extensive information on the medical condition<br/>• Encouragement to get early active <br/>• Active exercises to encourage metabolism <br/>• Improvement of flexibility and strength<br/>• Medication: painkiller, muscle relaxants<br/>Furthermore physiotherapists use mechanical traction as a type of treatment. By use of a simple device some pressure is taking of the spine, primarily to improve symptoms in the leg.<br/>No scientific study has investigated yet whether an intensive home traction utilizing a technical device applied regularly by the patient, is more effective than treatment without this kind of traction.<br/>The current research project is evaluating whether the supplementary treatment with regularly applied home traction with two different levels of intensity over a period of two weeks, is more effective than the current best practice (see above). ";"Current clinical research in the area of low back pain favors subgrouping of patients according to clinical signs and symptoms. Classifying into subgroups should be guided by the individually most effective treatment. Patients with acute and subacute Sciatica due to a disc prolapse are an important subgroup. They show a high risk of long time chronificity and are potential candidates for surgical therapies. <br/>Unfortunately clear guidelines on conservative therapy for these patients are lacking. Recent studies propose mechanical traction as a treatment option for this specific subgroup. Former studies on this intervention did neither proof their efficiency nor did they confirm their uselessness.<br/>The current study will evaluate the efficiency of intensive mechanical home traction on patients with acute and subacute low back pain with predominant, non-centralizing leg pain and nerve root involvement in comparison with home traction of lower intensity. <br/>The research project evaluates to what extent the intervention mechanical home traction has some effect on quality of life. <br/>The results of the study can contribute to the development of a clinical prediction rule for the effective use of mechanical traction in back pain patients.<br/>The scheduled project will be a randomized controlled doubled blinded trial with patients fulfilling the inclusion criteria. Initial assessment and outcome measures will be carried out after two weeks, six weeks and one year. Patients in the treatment group will apply during two weeks intensive home- traction up to 2/3 of body weight using an auto-traction device. Patients in the control group will follow the same protocol but apply less intensive traction up to 20 % of body weight. <br/>Patients in both groups receive extensive information on pathology and prognosis of the condition. All patients will be encouraged to stay or get active. <br/>The included subgroup represents a patient group with a high risk for chronificity and increasing costs. The study could contribute to define evidence based treatment recommendations for a subgroup which lacks straight forward conservative treatment strategies despite of a high level of disability. <br/><br/>";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004250";"2013-11-23T00:56:00.129+01:00";
"DRKS00004886";2013/04/17;"[---]*";yes;"Approved";"EA4/019/13";"Ethik-Kommission der Charité -Universitätsmedizin Berlin-";;;;;;;;;;;;;;;;"ICD10";"I34.0";"Mitral (valve) insufficiency";"ICD10";"R11";"Nausea and vomiting";"ICD10";"F05.8";"Other delirium";"ICD10";"I24";"Other acute ischaemic heart diseases";;;;"Arm 1";"Total intravenous anaesthesia (TIVA: Propofol + Remifentanil) for percutanuous correction of severe mitral regurgitation with the MitraClip-System.";"Arm 2";"Balanced anaesthesia (Desflurane + Remifentanil) for percutanuous correction of severe mitral regurgitation with the MitraClip-System.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control";"Treatment";"Parallel";"N/A";"No";"troponin I release 24 hours after induction of general anaesthesia";"- myocardial infarction, defined as new Q-wave >= 40 ms in at least two corresponding  leads or loss of R-wave in V1 to V6 or TnI >11,6 µg/l 24h post induction of general anaesthesia<br/><br/>- changes in ST-segment during or after intervention<br/><br/>- maximum decrease of cardiac output during intervention as measured with thermodilution method (PiCCO®) and with transesophageal echocardiography (TEE) immediately before and after induction of general anaesthesia, after 30 min, after mitral clipping and at the end of the procedure<br/><br/>- maximum decrease in mid arterial pressure during intervention <br/><br/>- accumulated time of hypotension defined as systolischer arterial pressure > -20% (compared to systolic blood pressure at time of assesment for anaesthesia) or mid arterial pressure (MAD) < 60 mmHg <br/><br/>- accumulated dosage of vasopressors and/or ionotropes (noradrenalin, adrenalin, dobutamin) during intervention<br/><br/>- conditions for intervention<br/><br/>- duration of intervention<br/><br/>- intensive care and hosptal length of stay (days)<br/><br/>- incidence of post-interventional delirium<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Charité - Universitätsmedizin Berlin";"Berlin";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/04/19;"Actual";"84";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"•	age>18 years<br/>•	informed consent for MitraClip®<br/>•	informed consent for general anaesthesia<br/>•	informed consent of anaesthesiologist<br/>";"•	age <18 years<br/>•	missing informes consent<br/>•	myocardial infarction during last 6 weeks before intervention<br/>•	contraindications against Propofole, inhalative anaesthetics, Remifentanil, CisAtracurium<br/>•	use of sulfonylurea, theophylline or allopurinol <br/>•	history of inguinal vascular surgery<br/><br/>";"Primary Sponsor";"Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin<br/>Charité - Campus Benjamin Franklin";"[---]*";"[---]*";"[---]*";"[---]*";"Hindenburgdamm 30";"12203";"Berlin";"Germany";"030 - 8445 2733";"[---]*";"[---]*";"www.charite.de";"Contact for Scientific Queries";"Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin<br/>Charité - Campus Benjamin Franklin";"Mr.";"Dr. med.";"Jan ";"Kügler";"Hindenburgdamm 30";"12203";"Berlin";"Germany";"030 - 8445 2733";"[---]*";"jan.kuegler@charite.de";"www.charite.de";"Contact for Public Queries";"Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin<br/>Charité - Campus Benjamin Franklin";"Mr.";"Dr. med.";"Jan";"Kügler";"Hindenburgdamm 30";"12203";"Berlin";"Germany";"030 - 8445 2733";"[---]*";"jan.kuegler@charite.de";"www.charite.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Charité Campus Benjamin Franklin";"[---]*";"[---]*";"[---]*";"[---]*";"Hindenburgdamm 30";"12203";"Berlin";"Germany";"[---]*";"[---]*";"[---]*";"www.charite.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A randomized controlled comparison of total intravenous anaesthesia and balanced anaesthesia for interventional repair of mitral regurgitation: myocardial ischemia and haemodynamics.";"[---]*";"[---]*";"The aim of this trial is to compare two different kinds of general anaesthesia, total intravenous anaesthesia and balanced anaesthesia, for the implantation of the MitraClip®-System. The main focus will be, whether the choice of anaesthesia influences the damage the heart might sustain during the procedure and whether the choice of anaesthesia influences blood pressure an cardiac function differently. <br/>To asses damage to the heart, Troponin I, a marker of myocardial cell death, will be measured 24 hours after induction of anaesthesia. Also, an electrocardiogram (ECG) will be taken at this time.<br/>During general anaesthesia  advanced haemodynamic monitoring will be implemented to asses cardiac function continuously. Therefore critical loss of cardiac function will be detected earlier and treated more easily.<br/>";"New catheter-based corrections of cardiac valve dysfunctions, like TAVI or MitraClip® are generally implanted with the patient in general anaesthesia.<br/>So far nothing is known whether the choice of anaesthetics  influences patients outcome after mitral clipping. However balanced anaesthesia compared to total intravenous anaesthesia for coronary artery bypass surgery is associated with less myocardial damage as measured with troponin I release while preconditioning with sevoflorane does not influence troponin I release during percutaneous coronary intervention. For surgical mitral valve repair only the subgroup of the patients with coronary artery disease had less troponin I release when treated with inhalational anaesthetics.<br/>In non-cardiac surgery the choice of anaesthetic does not influence the incidence of cardiac ischaemia.<br/>The aim of this study is to compare total intravenous anaesthesia and balanced anaesthesia for implantation of the MitraClip®-System. To asses myocardial damage  troponin I release will be measured 24 hours after induction of general anaesthesia.<br/>";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004886";"2013-11-30T10:00:26.419+01:00";
"DRKS00011033";2016/08/30;"[---]*";yes;"Approved";"100/16";"Ethik-Kommission des Fachbereichs Medizin der Philipps-Universität Marburg";;;;;;;;;;;;;;;;"Free text";"[---]*";"Comparison of negative pressure incisional therapy with conventional plaster in regard to post-surgical site infections after urgent laparotomies in acute cases of gastro-intestinal disorders.";;;;;;;;;;;;;"Arm 1";"After skin closure of laparotomy patients in the experimental intervention receive negative pressure incisional therapy (PREVENA™, KCI Medizinprodukte GmbH, Wiesbaden). <br/>The negative pressure plaster will remain 5 (+1) days. Within 30 (+7) days after surgery post-surgical site infections (A1-2 CDC-Classification) will be documented.";"Arm 2";"After skin closure of laparotomy patients in the control intervention receive a non-occlusive conventional plaster.The conventional plaster will remain at least 2 days. Within 30 (+7) days after surgery post-surgical site infections (A1-2 CDC-Classification) will be documented. ";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Rate of post-surgical site infections of category A1 (superficial) and A2 (deep) within 30 (+7) days after surgery in patients without revision.";"Prolongation of hospitalisation due to post-surgical site infection, <br/>cosmetic result, <br/>safety endpoints: AEs, SAEs. ";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Viszeral-, Thorax- und Gefäßchirurgie";"Marburg";"Medical Center";"Klinik für Allgemeine - und Viszeralchirurgie";"Bad Berka";"University Medical Center";"Klinik für Allgemeine-, Viszeral-, Thorax-, Transplantations- und Kinderchirurgie";"Gießen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2016/09/21;"Actual";"294";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"•Patients with indication for urgent laparotomy due to an acute gastro-intestinal disorder<br/>•age ≥ 18 years<br/>•life expectancy > 12 months<br/>•Written informed consent of the patient or the patient’s legal representative ";"•Inpatient treatment longer than 4 days before urgent surgery<br/>•Previous transverse or median laparotomy, if it is necessary to reopen it again <br/>•Allergy or hypersensitivity against silver or acrylic adhesives<br/>•pregnancy<br/>•participation in an interventional study with interfering endpoints<br/>•neurophysiological deficits<br/><br/>";"Primary Sponsor";"Philipps-Universität Marburg";"[---]*";"[---]*";"[---]*";"[---]*";"Biegenstraße 10";"35037";"Marburg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Klinik für Viszeral-, Thorax- und GefäßchirurgiePhilipps-Universität Marburg";"Ms.";"Dr. med.";"Katja";"Maschuw";"Baldingerstraße";"35043";"Marburg";"Germany";"0049 6421-58-69897";"[---]*";"maschuw@med.uni-marburg.de";"[---]*";"Contact for Public Queries";"Klinik für Viszeral-, Thorax- und GefäßchirurgiePhilipps-Universität Marburg";"Ms.";"Dr. med.";"Katja";"Maschuw";"Baldingerstraße";"35043";"Marburg";"Germany";"0049 6421-58-69897";"[---]*";"maschuw@med.uni-marburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Private sponsorship (foundations, study societies, etc.)";"Rhön-Klinikum-AG (RKA-Förderpool)";"[---]*";"[---]*";"[---]*";"[---]*";"Schlossplatz 1";"97616";"Bad Neustadt a. d. Saale";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Evaluation of negative pressure incisional therapy in urgent gastro-intestinal surgery for reduction of superficial surgical site infections compared to non-occlusive conventional plaster -<br/>A prospective, randomized, controlled, multicenter clinical trial<br/>";"NEPTUN";"[---]*";"There is evidence that the risk for surgical site infections can be reduced by using negative pressure plaster compared to conventional plaster. The negative pressure plaster closes the surgical wound for 5 days. The NEPTUN study will investigate if the use of negative pressure plaster will also reduce the risk for surgical site infections in urgent gastro-intestinal surgery.";"Evaluation of post-surgical negative pressure incisional therapy for primarily closed wounds after urgent gastro-intestinal laparotomy within 30 (+7) days after surgery in patients without revision. <br/>Negative pressure incisional therapy will be compared to non-occlusive conventional plaster with regard to post-surgical site infections (A1-2 CDC-Classification). ";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011033";"2019-04-03T12:11:59.347+02:00";
"DRKS00009506";2015/10/09;"[---]*";yes;"Approved";"RK_042015 und RK_092015_amd_042015";"Ethikkommission der Deutschen Gesellschaft für Psychologie (DGPs)";;;;;;;;;;;;;;;;"Free text";"[---]*";"self-medication: participants using a specific analgesic (ibuprofen, paracetamol, aspirin) for pain relief ";"Free text";"[---]*";"self-medication: participants using a specific antihistamine (dimetindene, loratadine, cetirizine) for itch relief ";;;;;;;;;;"Arm 1";"group itch 1 (n=18): participants read the package insert of the antihistamine. There are no clinical interventions.";"Arm 2";"group itch 2 (n=18): participants read an information focussing on self-efficacy. There are no clinical interventions.";"Arm 3";"group itch 3 (n=18): participants read a neutral information. There are no clinical interventions.";"Arm 4";"group pain 1 (n=18): participants read the package insert of the analgesic. There are no clinical interventions.";"Arm 5";"group pain 2 (n=18): participants read an information focussing on self-efficacy. There are no clinical interventions.";"Arm 6";"group pain 3 (n=18): participants read a neutral information. There are no clinical interventions.";;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Other";"Other";"Parallel";"N/A";"N/A";"Primary endpoints are the symptom reduction (numeric rating scale), medication intake and related side-effects collected via an online survey and a possible paper version (including STAI-S (anxiety), SETS (Stanford Expectations of Treatment Scale; measuring patient outcome expectancy in clinical trials ), PHQ-4 (anxiety and depression) at three points of time: baseline, post1 (after intervention) and post2 (couse over seven days).";"[---]*";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsklinikum Hamburg-Eppendorf";"Hamburg";"University Medical Center";"Charité";"Berlin";"other";"kooperierende Apotheken";"Hamburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/10/13;"Actual";"108";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"self-medication with an antihistamine (dimetindene/cetirizine/loratadine) to reduce itch intensity or selfmedication with an analgesic (ibuprofen/aspirin,paracetamol) to reduce pain";"- symptom intensity < 3 on a numeric rating scale (range 0 to 10)<br/>- acute and/or chronic psychiatric disorders (ICD-10) according to participant's statement<br/>- poor knowledge of the German language";"Primary Sponsor";"Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Anästhesiologie";"Ms.";"PD Dr.";"Regine";"Klinger";"Martinistraße 52";"20246";"Hamburg";"Germany";"[---]*";"[---]*";"r.klinger@uke.de";"[---]*";"Contact for Scientific Queries";"Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Anästhesiologie";"Ms.";"PD Dr.";"Regine";"Klinger";"Martinistraße 52";"20246";"Hamburg";"Germany";"+49(0)40-741052837";"[---]*";"r.klinger@uke.de";"[---]*";"Contact for Public Queries";"Universität Hamburg, Institut für Psychologie";"Ms.";"M.Sc. Psych.";"Ariane";"Sölle";"Von-Melle-Park 5";"20146";"Hamburg";"Germany";"040-42838-5374";"[---]*";"ariane.soelle@uni-hamburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgemeinschaft (aus Geldern der Programmpauschale der Projekte KL1350/5-1 und 1350/3-2)";"[---]*";"[---]*";"[---]*";"[---]*";"Kennedyallee 40";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.dfg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Optimization of the pharmacological component using additive placeboeffects: Is it possible to enhance the psychological component during self-medication by disclosing information about the psychological components";"[---]*";"[---]*";"We aim to investigate the impact of the information in package inserts of antihistamines (dimetindene, cetirizine, loratadine) and analgesics (paracetamol, ibuoprofen, aspirin) on the drug efficacy and on the occurring side effects of the drug. <br/>Participants are asked to fill out questionnaires (online version or paper-pencil version) and reading either a neutral information, the information given in the package insert of their medication, or an information focussing on self-efficacy.";"We aim to investigate the impact of the information in package inserts of antihistamines (dimetindene, cetirizine, loratadine) and analgesics (paracetamol, ibuoprofen, aspirin) on the drug efficacy and on the occurring side effects of the drug. <br/>Participants are asked to fill out questionnaires (online version or paper-pencil version) and reading either a neutral information, the information given in the package insert of their medication, or an information focussing on self-efficacy.";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009506";"2019-12-20T15:20:15.681+01:00";
"DRKS00013069";2017/10/02;"[---]*";yes;"Approved";"2017-070";"Medizinische Ethikkommission der Carl von Ossietzky Universität Oldenburg";;;;;;;;;;;;;;;;"ICD10";"F33.9";"Recurrent depressive disorder, unspecified";;;;;;;;;;;;;"Arm 1";"Magnetic resonance imaging (MRI) of the brain,  functional MRI, Magnetencephalography (MEG), Scoring of Beck-Depressions-Inventar, Snaith-Hamilton pleasure scale, Hamilton Depression Scale at the beginning and after CBASP-Therapy";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"N/A";"No";"<br/>Brain activity changes in different brain regions at the beginning and at the end of CBASP (Cognitive Behavioral Analysis System of Psychotherapy) therapy measured by functional magnetic resonance imaging";"Score changes of the questionnaires (Beck-Depressions-Inventar, Snaith-Hamilton pleasure scale, Hamilton Depression Scale) at the beginning and at the end of CBASP (Cognitive Behavioral Analysis System of Psychotherapy) therapy";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Karl-Jaspers-Klinik";"Oldenburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/10/23;"Actual";"30";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"patients with chronic depression who get a CBASP therapy";"patients who are younger than 18, patients who are not consentable, patients who take mood-stabilizer or Lithium, patients with MR-specific contraindication, e.g. pace maker etc.";"Primary Sponsor";"Medizinischer Campus Universität Oldenburg Fakultät für Medizin und GesundheitswissenschaftenUniversitätsklinik für Psychiatrie und Psychotherapie Karl-Jaspers-Klinik";"[---]*";"[---]*";"[---]*";"[---]*";"Hermann-Ehlers-Str. 7";"26160";"Bad Zwischenahn";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Medizinischer Campus Universität Oldenburg Fakultät für Medizin und Gesundheitswissenschaften Universitätsklinik für Psychiatrie und Psychotherapie";"Mr.";"Dr.";"Sebastian";"Möller";"Hermann-Ehlers-Straße 7";"26160";"Bad Zwischenahn";"Germany";"0441/9615-9144";"0441/9615-1599";"sebastian.moeller@uni-oldenburg.de";"[---]*";"Contact for Public Queries";"Medizinischer Campus Universität Oldenburg Fakultät für Medizin und Gesundheitswissenschaften Universitätsklinik für Psychiatrie und Psychotherapie";"Mr.";"Dr.";"Sebastian";"Möller";"Hermann-Ehlers-Straße 7";"26160";"Bad Zwischenahn";"Germany";"0441/9615-9144";"0441/9615-1599";"sebastian.moeller@uni-oldenburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Medizinischer Campus Universität OldenburgFakultät für Medizin und GesundheitswissenschaftenUniversitätsklinik für Psychiatrie und Psychotherapie";"Ms.";"Prof.";"Alexandra";"Philipsen";"Hermann-Ehlers-Str. 7";"26160";"Bad Zwischenahn";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Neural, cognitive, and emotional changes in patients with chronic Depression receiving Cognitive Behavioral Analysis System of Psychotherapy (CBASP) - an f-MRI-supported pilot study";"CBASP-Study";"[---]*";"In patients with chronic depression we want to examine whether the cognitive behavioral analysis system of psychotherapy (CBASP) leads to measurable changes within the brain or the circuitry of neurons. The effectiveness of CBASP has been proven. However, so far it is unclear on which the effect of the procedure is based on.<br/>This is the aim of the study. We want to use magnetic resonance imaging (MRI) of the brain and additional functional MRI, as well as magnetoencephalography (MEG) at the beginning and after the CBASP treatment. Additionaly, using standardized questionnaires, we want to determine whether CBASP leads to changes of joy and pleasure feeling, mood and fear experience. The questionnaires are as follows: the so-called Beck Depression Inventory (BDI), the Snaith-Hamilton pleasure scale, short SHAPS, and the Hamilton Depression Scale (HAMD).";"The target group of the study is patients suffering from chronic depression. In the context of specialized university treatment, the patients receive a therapy using the so-called Cognitive Behavioral Analysis System of Psychotherapy (CBASP). Proof of efficacy has been provided for this method in chronic depressive patients. For behavioral therapy, evidence of efficacy was also provided. The effect of behavioral therapy is most likely to be due to changes in the brain which become visible to currently available techniques of imaging, e.g. fMRT. At the same time, there are (still) no studies that investigate the new CBASP treatment method with regard to possible neuronal and neurovegetative effects.<br/>For this purpose, we would like to assess possible neuronal and vegetative effects by means of magnetic resonance tomography (MRI) of the brain and additional functional MRI examination as well as by means of magnetoencephalography (MEG) at the beginning and after the CBASP therapy.<br/>We would also like to examine the patients by means of various psychometric tests at the beginning and after CBASP therapy.<br/>The study investigated psychiatric symptoms such as anxiety, depression, anhedonia, and quality of life in patients and patients at baseline and after CBASP therapy.<br/>The underlying hypothesis is that CBASP therapy leads to measurable neurophysiological changes and, at the same time, correlates to the psychometric tests.";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00013069";"2019-10-27T14:51:58.482+01:00";
"DRKS00005696";2014/05/06;2014/01/28;no;"Approved";"MV-064/2009";"Ethik-Kommission I der Medizinischen Fakultät Heidelberg";"Primary Registry-ID";"NCT02049567";"ClinicalTrials.gov";;;;;;;;;;;;;"ICD10";"H25";"Senile cataract";;;;;;;;;;;;;"Arm 1";"Experimental: Implant<br/><br/>FluidVision Lens shall be surgically implanted to restore accommodative vision.";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"N/A";"N/A";"Objective accommodative amplitude after 6 months using an auto refractometer.<br/><br/>Best corrected distance visual acuity of logMAR of 0.3 or better.<br/><br/>Rates of serious adverse events at 6 months.";"[---]*";"DE";"Germany";"ZA";"South Africa";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Department of Ophthalmology Ruprecht-Karls University Heidelberg";"Heidelberg";"University Medical Center";"Center for Vision Science Ruhr University Eye Hospital";"Bochum";"Doctor's Practice";"[---]*";"Berlin";"Doctor's Practice";"[---]*";"Stuttgart";"Medical Center";"Optimed Eye and Laser Centre";"Pretoria";"Medical Center";"John Hill Eye Laser Centre";"Cape Town";"Medical Center";"Visiomed Laser Centre";"Johannesburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/01/10;"Actual";"115";"[---]*";"Multicenter trial";"International";"Both, male and female";"50";"Years";"[---]*";"no maximum age";"1.Patients must be eligible for primary intraocular lens implantation for the correction of aphakia following cataract extraction.<br/><br/>2.Patients should have a best corrected distance visual acuity worse than 20/40 either with or without a glare source present (e.g. Brightness Acuity Tester)<br/><br/>3.Patients predicted best corrected distance visual acuity must be 20/40 or better after cataract removal and AIOL implantation as determined by potential acuity meter (PAM) or other potential vision tests or surgeon estimation on both eyes.<br/>4.Patients must have ≤1.0 D of preoperative keratometric astigmatism.<br/>5.Patients must have clear intraocular media other than cataract.<br/>6.Patients must have a preoperative endothelial cell density of 2200 cells/mm2 or more.<br/>7.Patients must be at least 50 years of age.<br/>8.Patients must be willing and able to comply with schedule for follow-up visits for thirty six months after surgery.<br/>9.Patients must have a calculated AIOL power within the range of the investigational device;<br/>10.Patients must provide written informed consent.";"1.Patients must not be taking medications that may affect accommodation (including but not limited to mydriatic, cycloplegic and miotic agents; tricyclic antidepressants, phenothiazines, benzodiazepines, first generation antihistamines, and anticholinergic agents).<br/>2.Patients must not have systemic disease that could increase the operative risk or confound the outcome (e.g. autoimmune disease, diabetes).<br/>3.Patients must not have systemic medications that may confound the outcome or increase the risk to the subject i.e tamsulosin hydrochloride (Flomax) or other medications with similar side effects.<br/>4.Patients must not have ocular conditions that may predispose for future complications (e.g. anterior segment pathology including glaucoma or potentially occludable angles, corneal dystrophy, ocular inflammation, poor pupil dilation).<br/>5.Patients must not have previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject.<br/>6.Patients must not be pregnant, lactating during the course of the investigation, or has another condition with associated fluctuation of hormones that could lead to refractive changes.<br/>7.Patients must not have degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future best corrected visual acuity loss worse than 20/40.<br/>8.Patients must not have conditions that increase the risk of zonular rupture during cataract extraction procedure that may affect the postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome).<br/>9.Patients must not have sensitivity to planned study medications.<br/>10.Patients must not be simultaneously participating in other ophthalmic drug or device clinical trial.<br/>11.Patients who do not have an intact capsulorhexis and posterior capsular bag at the time of cataract extraction and lens implantation.<br/>12.Patients who have floppy/weak zonules, incomplete zonules or zonular rupture during cataract extraction.<br/>13.Patients who have a capsulorhexis size of <5.5 mm or >6.0 mm.<br/>14.Patients who have a decentered capsulorhexis of >1.0 mm in relation to the limbus.<br/>15.Patients with posterior capsular opacity observed after cataract extraction.<br/>16.Patients with complicated cataract surgery or damage to AIOL that prevents implantation of the AIOL (e.g. pupillary constriction, poor visibility due to corneal edema).";"Primary Sponsor";"PowerVision, Inc.";"Ms.";"OD";"Priya";"Janakiraman";"260 Harbor Blvd";"94070";"Belmont";"United States";"650.620.9948x229";"650.620.4607";"pjanakiraman@powervisionlens.com";"[---]*";"Contact for Scientific Queries";"PowerVision, Inc.";"Mr.";"M.D.";"Raymund";"Angeles";"260 Harbor Blvd";"94002";"Belmont";"United States";"650.620.9948x249";"650.620.4607";"rangeles@powervisionlens.com";"[---]*";"Contact for Scientific Queries";"Department of Ophthalmology Ruprecht-Karls University Heidelberg";"Mr.";"Prof. Dr. med";"Gerd";"Auffarth";"INF 400";"D-69120";"Baden-Württemberg";"Germany";"+49-6221-5636631";"[---]*";"gerd.auffarth@med.uni-heidelberg.de";"[---]*";"Contact for Public Queries";"PowerVision, Inc.";"Ms.";"OD";"Priya";"Janakiraman";"260 Harbor Blvd";"94070";"Belmont";"United States";"650.620.9948x229";"650.620.4607";"pjanakiraman@powervisionlens.com";"[---]*";;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"PowerVision, Inc.";"[---]*";"[---]*";"[---]*";"[---]*";"260 Harbor Boulevard";"94070";"Belmont";"United States";"650.620.9948";"650.620.4607";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Clinical Evaluation of the FluidVision Accommodating Intraocular Lens";"AIOL-2009-1";"[---]*";"Traditional lenses for cataract patients are monofocal, meaning they offer clear distance vision, but that patients must wear eyeglasses or contact lenses in order to see clearly things that are close to them, such as a newspaper.<br/><br/>The FluidVision™ lens that is being tested in this study is designed to allow patients to see far objects as clearly as with a regular lens, and also to see near objects more clearly than with a regular lens.<br/>";"The FluidVision lens is an IOL that utilizes the eye's natural accommodative forces to reshape the anterior surface of the lens to change optical power. It does this by using a proprietary hydraulic mechanism to drive fluid from the periphery of the device to the central lens portion and back again, changing the curvature of the lens surfaces and facilitating accommodation.<br/>";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005696";"2014-12-15T19:06:03.415+01:00";
"DRKS00011507";2017/06/09;"[---]*";yes;"Approved";"2016-645N-MA";"Medizinische Ethik-Kommission II Medizinische Fakultät Mannheim der Universität Heidelberg";;;;;;;;;;;;;;;;"ICD10";"F10.2";"Mental and behavioural disorders due to use of alcohol; Dependence syndrome";"ICD10";"F11.2";"Mental and behavioural disorders due to use of opioids; Dependence syndrome";"ICD10";"F12.2";"Mental and behavioural disorders due to use of cannabinoids; Dependence syndrome";"ICD10";"F15.2";"Mental and behavioural disorders due to use of other stimulants, including caffeine; Dependence syndrome";"ICD10";"F13.2";"Mental and behavioural disorders due to use of sedatives or hypnotics; Dependence syndrome";"Arm 1";"Dyadic gamified approach-avoidance training in addition to treatment in the qualified detox programme; six session over the course of two weeks";"Arm 2";"Treatment as usual";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"I-II";"N/A";"As primary endpoints, we define the attentional bias scores and approach bias scores, measured with the dot-probe task and the AAT, respectively for substance-related image and word stimuli. Both measures will be repeated in both groups after twoo weeks.<br/>- Dot-probe-task (DPT):<br/>The dot-probe-task  assesses the selective attention towards alcohol-related and emotional stimuli. Pairs of images will be presented on a computer screen for 50 milliseconds (alcohol-related/neutral, fearful/neutral faces). Then a dot will appear, to which the participants are supposed to react by pushing a button as fast as possible. If the dot appears on the left side of the screen, they are supposed to push with the left index finger. If the dot appears on the right side of the screen, they are supposed to react with the right index finger.<br/><br/>- Approach avoidance task (AAT):<br/>The approach-avoidance task assesses the approach tendency towards substance-related stimuli and neutral stimuli.  On a computer screen, images are presented in portrait or landscape format. Depending on the format, participants are supposed to push away or pull a joystick within 2 seconds. After 20 training trials, 40 trails with substance-related stimuli and 40 trials with neutral stimuli will take place. The difference in response time can be used as a measure for the approach tendency. <br/>";"The following instruments will be used in both groups: <br/>- Visual analogue scales for assessing grade of addiction, craving and self-efficacy<br/>- standardised assessment of previous drinking and consumption behaviour (Form 90) (Scheurich et al., 2005)<br/>- standardised assessment of sociodemographic data: sex, age, education, occupational qualifications<br/>- Brief Symptom Inventory (BSI) (Derogatis & Savitz, 1999)<br/>- Obsessive Compulsive Drinking Scale (OCDS, (Mann & Ackermann, 2000)) <br/>- Craving Automated Scale for Substances (CAS-S) (H.; Nakovics et al., 2012) <br/>- Mannheimer Craving Scale (MaCS, H. Nakovics, Diehl, Geiselhart, & Mann, 2009)<br/>- Biogenetic and socio-dynamic causal attribution for the development of addiction (Heberlein et al., 2014)<br/>- Modification of the Hanil Alcohol Insight Scale (Kim, Kim, Lee, Lee, & Oh, 1998)<br/>- Modification of the Alkohol-Abstinence Self-Efficacy-Scale (AASE; (McKiernan et al., 2011)<br/><br/>After two weeks the following questiionnaires will be repeated: BSI, MACS, CASS, HAIS, AASE and  Biogenetic and socio-dynamic causal attribution<br/><br/>The following neuropsychological assessments will be conducted in the initial and final assessment in addition to dot-probe-task and AAT in both groups: <br/>- Implicit Association Test (IAT): Approach tendency towards substance related stimuli<br/>- Stroop Task: executive control over automatic processes<br/><br/>After every training session the patients of the intervention group will locate their craving on a visual analogue scale.<br/><br/>Additionally, the participants of the intervention group will answer standardised questions about the usefulness, effectiveness and satisfaction with the training after the completion of six sessions.<br/><br/>Three months after discharge the consumption behaviour of the participants will be assessed again in a follow up interview over the telephone.<br/><br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Zentrum für Psychiatrie Nordbaden";"Wiesloch";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/02/22;"Actual";"60";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"65";"Years";"- At least one diagnosed dependency on alcohol, pharmaceuticals, cannabis and/or amphetamines <br/>- Written informed consent<br/>";"- Failure to supply or withdrawal of written informed consent<br/>- No telephone contact possible, no permanent address<br/>- Inadequate oral and written knowledge of the German language<br/>- Known pregnancy <br/>- Schizophrenia or psychotic disorders<br/>- Dementia<br/>- Serious somatic illnesses that would impair the questioning or the participation in the dyadic gamified approach-avoidance training<br/>- Acute suicidality<br/>";"Primary Sponsor";"Zentralinstitut für Seelische GesundheitKlinik für Abhängiges Verhalten und Suchtmedizin";"Mr.";"Dr. sc. hum.";"Ulrich";"Frischknecht";"J5";"68159";"Mannheim";"Germany";"0621 1703-3926";"[---]*";"ulrich.frischknecht@zi-mannheim.de";"https://www.zi-mannheim.de/";"Contact for Scientific Queries";"Zentralinstitut für Seelische GesundheitKlinik für Abhängiges Verhalten und Suchtmedizin";"Mr.";"Dr. sc. hum.";"Ulrich";"Frischknecht";"J5";"68159";"Mannheim";"Germany";"0621 1703-3926";"[---]*";"ulrich.frischknecht@zi-mannheim.de";"https://www.zi-mannheim.de/";"Contact for Public Queries";"Zentralinstitut für Seelische GesundheitKlinik für Abhängiges Verhalten und Suchtmedizin";"Mr.";"Dr. sc. hum.";"Ulrich";"Frischknecht";"J5";"68159";"Mannheim";"Germany";"0621 1703-3926";"[---]*";"ulrich.frischknecht@zi-mannheim.de";"https://www.zi-mannheim.de/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Zentralinstitut für Seelische GesundheitKlinik für Abhängiges Verhalten und Suchtmedizin";"[---]*";"[---]*";"[---]*";"[---]*";"J5";"68159";"Mannheim";"Germany";"0621 1703-3926";"[---]*";"[---]*";"https://www.zi-mannheim.de/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"The influence of a dyadic gamified approach-avoidance training on attentional bias and approach tendency in addicted patients: a pilot study";"[---]*";"[---]*";"A lot of addicted patients automatically react to certain stimuli, for example pictures or names of addictive substances, with approach behaviour or an attentional shift towards the stimulus. These automatic reactions are often connected to relapse. We want to examine whether a gamified pair exercise can influence these automatic attentional and approach tendencies in order to improve the treatment of patients with strong tendencies of that kind in the future.<br/>Our plan is to recruit patients who are participating in the qualified detox programme in an addiction clinic and to do an initial assessment with them, including questionnaire to measure craving, substance consumption and believed about the causes of addiction. In addition to the questionnaire, we want to measure the attentional shift and approach tendency towards substance-related stimuli in a neuropsychological assessment. In this context, substance-related and neutral pictures and words will be presented on a computer screen in order to measure the reaction towards them. After completing the initial assessment, participants will be randomly assigned to one of two groups. Group 1 will receive a dyadic gamified training in addition to the usual treatment in the addiction clinic. The second group serves as a control group for the natural process and will not receive any additional interventions. <br/>The dyadic gamified training is a modification of a computerized treatment which is already applied in therapeutic practice. During their stay at the addiction clinic the patients of group 1 will be able to take part in six sessions of the training.<br/>After two weeks, the assessment of the automatic reactions will be repeated as well as the questionnaires. We want to test whether the attentional shift and approach tendencies have decreased. Three months after discharge we also want to question the participants about their consumption behaviour. <br/>Our goal is to test the following hypotheses:<br/>1.	Patients with substance use disorders in the training group as well as in the comparison group exhibit an attentional bias  towards substance-related in contrast to neutral stimuli.<br/>2.	The attentional bias decreases over the course of the addiction treatment.<br/>3.	The attentional bias decreases to a higher extent in patients in the training group than in patients in the comparison group over the course of the addiction treatment. <br/>4.	The impulse control of patients with substance use disorders improves over the course of the addiction treatment.<br/>5.	The impulse control improves to a higher extent in patients that participate in the training than in patients that do not participate. <br/><br/>An explorative question is concerned with whether patients that participate in the training report a different concept of their disease and a changed abstinence self-efficacy compared to patients who don’t participate in the training.<br/>";"The modification of automatic direction of attention and action tendencies through specific trainings are counted among the most important advances in the therapy of substance-related disorders (Wiers, Eberl, Rinck, Becker, & Lindenmeyer, 2011). Trainings are applied to modify cognitive biases and automatic approach tendencies, as they are found in patients with substance dependence (Vollstadt-Klein et al., 2012; Vollstädt-Klein et al., 2011). In a study by Wiers et al. (2009), the participants of an alcohol-approach-avoidance-task were instructed to react to images, depending on their quality, with an approach-motion (pulling a joystick towards oneself) or an avoidance-motion (pushing the joystick away from oneself) (Wiers, Rinck, Dictus, & van den Wildenberg, 2009). Heavy drinkers showed an attentional bias towards alcohol-related images. Further research demonstrated that participants’ instruction to react to alcohol-associated stimuli with an avoidance-like motion was linked to reduced alcohol intake (Wiers, Rinck, Kordts, Houben, & Strack, 2010). In a first clinical study on alcohol-dependent patients, the training showed an advantageous effect and resulted in a ca. 13% lower relapse rate one year after discharge (Wiers et al., 2011). An additional analysis showed that the training is ideally conducted in six sessions (Eberl et al., 2014). <br/>In order to improve the variety of trainings for the modification of maladaptive cognitive biases, it has been proposed to include game elements (Boendermaker, Prins, & Wiers, 2015). To ensure a broader availability of these interventions, smartphone-based variations of these trainings are being tested (Garnett, Crane, Michie, West, & Brown, 2016). Furthermore it was suggested to integrate interactive or social elements in gamified approaches of cognitive bias modification trainings (Boendermaker, Boffo, & Wiers, 2015). From studies on selective attentional bias in substance use disorders we know that the expected effect also occurs when words are used as substance-related stimuli, especially when the substance-related words are personally relevant. Thus, it was shown in a study with heavy drinkers that only the response time in a stroop task with individualised, alcohol-related words could predict drinking behaviour (Christiansen & Bloor, 2014). Likewise, Cox, Hogan, Kristian, and Race (2002) demonstrated the use of individualised stimuli in the form of preferred beverage brands to predict the course of treatment in patients with alcohol abuse.<br/>Hence, a gamified training was developed, in which the participants in pairs (dyadic) take turns in reacting to verbal, personally relevant, substance-related stimulus words with an avoidance motion, and by contrast reacting to words that connect to an improved chance of abstinence with an approach motion.<br/>In the study, both attentional and approach bias towards substance-related stimuli in patients with substance use disorders shall be compared between participants and non-participants of a dyadic gamified approach-avoidance training. Furthermore, the influence of the training on craving and on subjective concepts of disease shall be examined. It shall also be examined if participants of the training demonstrate a bigger change in attentional or approach bias towards substance-related stimuli compared to non-participants.<br/>The following hypotheses shall be examined: 1.	Patients with substance use disorders in the training group as well as in the comparison group exhibit an attentional bias  towards substance-related in contrast to neutral stimuli.<br/>2.	The attentional bias decreases over the course of the addiction treatment.<br/>3.	The attentional bias decreases to a higher extent in patients in the training group than in patients in the comparison group over the course of the addiction treatment. <br/>4.	The impulse control of patients with substance use disorders improves over the course of the addiction treatment.<br/>5.	The impulse control improves to a higher extent in patients that participate in the training than in patients that do not participate. <br/>An explorative question is concerned with whether patients that participate in the training report a different concept of their disease and a changed abstinence self-efficacy compared to patients who don’t participate in the training.<br/>For testing these hypotheses participants will be recruited in the wualified detox program of an addiction clinic. The participants will be randomly assigned to two groups. Both groups will partake in an initial assessment, consisting of neuropsychological tests (dot-probe, IAT, AAT, Stroop task) and a variety of questionnaire assessing consumption behaviour, craving and subjective concept of disease. In the following two weeks the intervention group will get six sessions of the dyadic gamified approach avoidance training in addition to the qualified detox programme. The control group gets the treatment as usual in the qualified detox programme. After two weeks, both groups will undergo a repetition of the neuropsychological and psychometric tests.<br/><br/><br/>";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011507";"2019-05-22T18:53:00.559+02:00";
"DRKS00008840";2015/07/29;"[---]*";yes;"Approved";"199/2015BO1";"Ethik-Kommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen";;;;;;;;;;;;;;;;"ICD10";"F00";"Dementia in Alzheimer disease";"ICD10";"F32";"Depressive episode";"ICD10";"F33";"Recurrent depressive disorder";"ICD10";"F06.7";"Mild cognitive disorder";"ICD10";"F01";"Vascular dementia";"Arm 1";"Neuropsychological Test Battery (CERAD plus; Memory Clinic Basel)<br/>Depression Screening (affective state),<br/>Creating drawings on the tablet";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Diagnostic";"Single (group)";"N/A";"N/A";"early diagnosis of dementia,<br/> positive predictive value mind. 90%";"capable of overcoming shortcomings<br/>in current medical diagnostics, differential diagnosis of chronic depression, a completion of medical tests, a simple status investigation and a competent monitoring,  measurement of the variation of the state of mind on a given day";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Memory Clinic";"Tübingen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/08/01;"Actual";"120";"[---]*";"Monocenter trial";"National";"Both, male and female";"49";"Years";"[---]*";"no maximum age";"physically able to meet the testing requirements,<br/>sufficient language ability (German),<br/>sufficient (corrected) normal visual acuity,<br/>sufficient (corrected) hearing ";"Pregnant and lactating women.<br/>Persons who are held in an institutional custody due to cort order or administrative order.<br/>Participants with physical disabilities that affect his or her ability to carry out the required tasks.";"Primary Sponsor";"Hochschule für Kunsttherapie Nürtingen";"Mr.";"Prof.";"Ulrich";"Elbing";"Sigmaringer Str.15/2";"72622";"Nürtingen";"Germany";"07022/ 933360";"[---]*";"u.elbing@hkt-nuertingen.de";"www.hkt-nuertingen.de";"Contact for Scientific Queries";"Hochschule für Kunsttherapie Nürtingen";"Mr.";"Prof.";"Ulrich";"Elbing";"Sigmaringer Str. 15/2";"72622";"Nürtingen";"Germany";"07022/933360";"[---]*";"u.elbing@hkt-nuertingen.de";"www.hkt-nuertingen.de";"Contact for Public Queries";"Universitätsklinik für Psychiatrie und Psychotherapie";"Mr.";"Dr.";"Stephan";"Mülller";"Calwer Str. 14";"72076";"Tübingen";"Germany";"07071/2982294";"[---]*";"stephan.mueller@med.uni-tuebingen.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministrium für Wirtschaft und EnergieKooperationsprojekteAiF Projekt GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Tschaikowskistraße 49";"13156 ";"Berlin";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Development and validation of a hard- and software based procedure for dementia diagnose, monitoring and image documentation obtained by the creative painting and drawing pocess of patient images";"ZIM-Project";"[---]*";"In this study we develop an easily applicable digital screening method with the aim of being able to distinguish between an early stage of Alzheimer´s dementia and a normal age-related cognition weakness.";"In the dementia diagnostics many tests in the field of analyzing handwritten drawings, for example the clock drawing test, are well established. However there are restrictions regarding the evaluation of the production of the drawing. Ductus, holding and releasing of the pen and drawing speed cannot be recorded and measured, but which provide important evidences about the extent of the cognitive impairment. The idea of this study is to use modern capturing devices such as tablets to allow the detailed documentation of the diagnostic criteria of the patient´s drawing process. This study deals with the development and validation of a digital drawing device in order to be able to gather a variety of art therapeutic relevant fingerprints in patient images and to evaluate them for diagnosis. The objective is to use this hard- and software based screening method in the early diagnostics of Alzheimer´s disease.";"Recruiting suspended on temporary hold ";"Paper";"[---]*";"[---]*";"Müller, S., Preische, O., Heymann, P., Elbing, U., and Laske, C. “Diagnostic Value of a Tablet-Based Drawing Task for Discrimination of Patients in the Early Course of Alzheimer’s Disease from Healthy Individuals.” Journal of Alzheimer’s Disease 55.4 (2016): 1463–1469. CrossRef. Web.";"Paper";"[---]*";"[---]*";"Müller, S., Preische, O., Heymann, P., Elbing, U. and Laske, C. ""Increased Diagnostic Accuracy of Digital vs. Conventional Clock Drawing Test for Discrimination of Patients in the Early Course of Alzheimer’s Disease from Cognitively Healthy Individuals"" Front Aging Neurosci 9: 101 (2017): doi:  10.3389/fnagi.2017.00101 ";;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00008840";"2017-10-19T13:58:38.564+02:00";
"DRKS00011702";2017/03/06;"[---]*";yes;"Approved";"139/2016";"Ethik-Kommission der Universität Witten/Herdecke";;;;;;;;;;;;;;;;"ICD10";"G82.12";"[generalization G82.1: Spastic paraplegia]";"ICD10";"G82.13";"[generalization G82.1: Spastic paraplegia]";;;;;;;;;;"Arm 1";"Arm 1- Treatment with physical electromagnetic therapy <br/>for 2x16 minutes a day over 6 consecutive Weeks";"Arm 2";"Arm 2 - Placebo - Patient is placed on BEMER System which does not generate a magnetic field. The System is not distinguishable from a ""normal"" system";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"N/A";"N/A";"Spasm reduction on Ashcroft and Penn Scale<br/>after a six-week Treatment with physical electromagnetical therapy";"Pain reduction (VAS)<br/>reduction of spastic-related medication<br/>increase of QoL<br/><br/>after a Treatment of 6 consecutive weeks";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"BG Klinikum Duisburg";"Duisburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/03/27;"Actual";"92";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"65";"Years";"Chronic or acute spastic paraplegia.";"According to our knowledge there is no exclusion criteria for the use of pulsed electromagnetic therapy";"Primary Sponsor";"BG Klinikum Duisburg gGmbH";"Mr.";"Dr.";"Jansoch";"Dahmen";"Großenbaumer Allee 250";"47249";"Duisburg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"BG Klinikum Duisburg gGmbh";"Mr.";"Dr.";"Matthias";"Rüschenschmidt";"Großenbaumer Allee 250";"47249";"Duisburg";"Germany";"0203 7688 3758";"[---]*";"matthias.rüschenschmidt@bg-klinikum-duisburg.de";"[---]*";"Contact for Public Queries";"BG Klinikum Duisburg";"Mr.";"Dr.";"Tobias";"Ohmann";"Großenbaumer Allee 250";"47249";"Duisburg";"Germany";"0203 7688 3129";"0203 7688 443129";"tobias.ohmann@bg-klinikum-duisburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"BG Klinikum Duisburg gGmbH";"Mr.";"Dr.";"Tobias";"Ohmann";"Großenbaumer Allee 250";"47249";"Duisburg";"Germany";"0203 7688 3129";"0203 7688 443129";"tobias.ohmann@bg-klinikum-duisburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Influence of physical electromagnetic therapy on spasticity and pain in chronic paraplegia";"[---]*";"[---]*";"[---]*";"The study examines the influence of physical electromagnetic therapy on spasticity and pain in chronic paraplegia. For the investigation a prospective randomized placebo controlled design was chosen. 46 patients with chronic complete or incomplete paraplegia will receive a daily physical electromagnetic therapy for 6 weeks. A control group will undergo a placebo treatment. Participants, physicians and physiotherapist are blinded to the treatment regimen. Modified Ashworth Spastic Scale, Modified Penn Spastic Frequency Scale, SF 36, VAS and SCIM will be observed. A 12-month period of investigation is planned.<br/><br/>Current literature supports that a pulsed electromagnetic therapy can improve bladder control, cognitive function, mobility and visual faculty in multiple sclerosis. (Lappin MS, Lawrie FW, Richards TL, Kramer ED, Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: A double-blind, placebo controlled trial. Altern Ther Health Med 2003;9:38-48). Nielsen et. al report a reduction of spasticity after application of a spinal magnetostimulation in multiple sclerosis. (Nielsen JF, Sinkjaer T, Long-lasting depression of soleus motoneurons excitability following repetitive magnetic stimuli of the spinal cord in multiple sclerosis patients, Multiple Sclerosis 1997;3:18-30). According to our knowledge, there are no comparable studies that examine the influence of a pulsed electromagnetic therapy on paraplegia.<br/>";"Recruiting suspended on temporary hold ";"Approval of ethics comm. (mandatory for transfer to Studybox)";"c4ee310e-791a-4f79-8b9d-a40d6d5f6399";"Ethikvotum_139_2016.pdf";"Ethikvotum 139_2016";"trial protocol (mandatory for transfer to Studybox)";"ebdfaf8b-a4ec-4803-9a60-28c22ab5ee2f";"Studienprotokoll_final.pdf";"Prüfplan_final";;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011702";"2019-08-01T14:05:44.121+02:00";
"DRKS00010223";2017/12/04;"[---]*";no;"Approved";"17-110";"Ethik-Kommission der Medizinischen Fakultät der Universität zu Köln";;;;;;;;;;;;;;;;"ICD10";"I34.0";"Mitral (valve) insufficiency";;;;;;;;;;;;;"Arm 1";"This is an observational study and will evaluate results by comparing pre-operative measurements to post-operative measurements";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"IV";"[---]*";"Reduction in Mitral Regurgitation from baseline to 6 months by TTE (transthoracic echocardiogram) evaluation";"Preservation/improvement in Left Ventricular health (dimensions, volume, etc.) based on changes in NYHA (New York Heart Association) status and TTE";"DE";"Germany";"CZ";"Czech Republic";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"[---]*";"Cologne";"University Medical Center";"[---]*";"Hamburg";"Medical Center";"[---]*";"Homolka";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/08/09;"Actual";"60";"[---]*";"Multicenter trial";"International";"Both, male and female";"21";"Years";"[---]*";"no maximum age";"a)  Patient is 21 years of age or older.<br/>b) Patient has symptomatic moderate to severe (3+ MR) or severe (4+ MR), chronic,  mitral regurgitation<br/>c) Patient is a candidate for mitral valve repair surgery with cardiopulmonary bypass with or without concomitant cardiac surgeries, such as CABG, MAZE, or surgical treatment of other valves.<br/>d) Mitral regurgitation must meet the following criteria:<br/>i. The primary regurgitant jet is central, originating from mal coaptation of anterior and posterior leaflets of the mitral valve.<br/>ii. If a secondary jet is present, the jet must be considered clinically insignificant. <br/>e) Women of child-bearing potential have a negative pregnancy test. <br/>";"a) Evidence of severe mitral annular and leaflet calcification.<br/>b) Patient is hemodynamically unstable.  <br/>c) Patient has Left Ventricular Dysfunction as defined by EF<25% or LVEDD >70mm<br/>d) Patient has hypertrophic cardiomyopathy and has systolic anterior motion of the leaflets.<br/>e) Patient requires emergency surgery.<br/>f) Patient has echocardiographic evidence of endocarditis or rheumatic heart disease.<br/>g) Transesophageal Echocardiogram (TEE) is contraindicated or cannot be performed intraoperatively for any reason.<br/>h) Patient has known chronic, dialysis-dependent renal failure.<br/>i) History of stroke, TIA or reversible ischemic neurological disease within the last three (3) months.<br/>j) History of gastrointestinal bleeding within the last three (3) months.<br/>k) History of hypersensitivity or allergy to aspirin<br/>l) History or hypersensitivity to clopidogrel (Plavix) or its congeners.<br/>m) Active or treated malignancies in the last twelve (12) months.<br/>n) Patient is participating in another clinical study for which follow-up is currently ongoing.<br/>o) Women of child-bearing age who have not had a negative pregnancy test.<br/>p) Patient with non-cardiac co-morbidities and life expectancy < 1 year.<br/>q) Patient has a condition that, in the opinion of the Investigator, precludes participation, including willingness to comply with all follow-up procedures.";"Primary Sponsor";"Corporate Sponsor";"Ms.";"[---]*";"Heart Repair Technologies, Inc. ";"[---]*";"18655 Madrone Parkway Ste. 180";"95037";"Morgan Hill";"United States";"+1 510-507-0595";"+1 408-779-2385";"mbaldwin@hrt-medical.com";"[---]*";"Contact for Scientific Queries";"VP RA/CA/QAHeart Repair Technologies, Inc.";"Ms.";"[---]*";"Marianne";"Baldwin";"18655 Madrone Parkway Ste. 180";"95037";"Morgan Hill";"United States";"+1-510-507-0595";"[---]*";"mbaldwin@hrt-medical.com";"[---]*";"Contact for Public Queries";"VP RA/CA/QAHeart Repair Technologies, Inc.";"Ms.";"[---]*";"Marianne";"Baldwin";"18655 Madrone Parkway Ste. 180";"95037";"Morgan Hill";"United States";"+1-510-507-0595";"[---]*";"mbaldwin@hrt-medical.com";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Heart Repair Technologies, Inc";"[---]*";"[---]*";"[---]*";"[---]*";"18655 Madrone Parkway Ste. 180";"95037";"Morgan Hill";"United States";"+1 408-659-6328";"[---]*";"mbaldwin@hrt-medical.com";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Post-Market Observational Study of the HRT MITRAL BRIDGE™ in Patients with Moderate to Severe Mitral Valve Regurgitation to Evaluate Device Safety and Performance";"[---]*";"[---]*";"This is a multi-center study to evaluate the safety and performance of a novel implant device for correction of mitral valve regurgitation.  The device is called the Mitral Bridge.  Patients will be followed for up to 12 months.<br/><br/>Patients may be enrolled in this study either as part of the surgical treatment of additional, cardiac conditions or for isolated mitral valve repair.<br/>";"This is a prospective, observational, multi-center study to evaluate the safety and performance of the Mitral Bridge device for correction of mitral valve regurgitation.  All patients will be followed for up to 12 months post-implantation.<br/><br/>Patients with symptomatic moderate to severe (3+) or severe (4+) mitral regurgitation, who are operative candidates and qualify for mitral valve repair as defined by the 2014 ACC/AHA recommendations for treatment of mitral regurgitation (Nishimura et al., 2014), will be approached regarding study participation.  Patients may be enrolled in this study either as part of the surgical treatment of additional, concomitant cardiac conditions or for isolated mitral valve repair.<br/>";"Recruiting suspended on temporary hold ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00010223";"2019-08-22T20:16:34.501+02:00";
